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Co-extrusion implies the simultaneous hot-melt extrusion of two or more materials 
through the same die, creating a multilayered extrudate. This innovative continuous 
production technology offers numerous advantages over traditional pharmaceutical processing 
techniques. Moreover co-extrusion provides great potential for the production of fixed-dose 
combination products which are gaining importance in pharmaceutical industry. Except from 
an implant (Implanon®) and a vaginal ring (Nuvaring®), there are no co-extruded dosage 
forms on the market so far. The aim of this work was to evaluate the potential of hot-melt co-
extrusion for the production of multilayer (core/coat) oral dosage forms. Possible applications 
are pointed out and polymers which can be combined in co-extruded dosage forms are 
selected.   
In the introduction, the equipment and downstream solutions for processing co-
extrudates into drug products are reviewed. Requirements and challenges in material 
selection, considering melt viscosity and multilayer adhesion are pointed out. Examples of 
medical and pharmaceutical applications are presented and some recent findings considering 
the production of oral drug delivery systems are summarized. Chapter 1 gives a brief 
overview of the polymer characteristics relevant for hot-melt co-extrusion (including 
solubility, hygroscopicity, toxicity, thermal stability, melt viscosity and extrudability). In 
chapter 2, fixed-dose combination dosage forms are developed by means of hot-melt co-
extrusion, the core providing sustained drug release and the coat immediate drug release. In 
chapter 3, hot-melt co-extrusion is assessed for the development of multilayered dosage 
forms characterized by a dual release profile of the same drug. In chapter 4, fixed-dose 
combination dosage forms are developed characterized by immediate release for both layers, 
the layers containing different drugs with different water-solubility. Chapter 5 is a critical 
evaluation of the co-extrusion process. This chapter questions if hot-melt co-extrusion offers 
an added value over hot-melt extrusion. 
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GENERAL INTRODUCTION 
Hot-melt co-extrusion: requirements, challenges 
and opportunities for pharmaceutical 
applications 
 
 
 
 
Parts of this chapter are published in: Vynckier, A.-K.*, Dierickx, L.*, Voorspoels, J., 
Gonnissen, Y., Remon, J. P. and Vervaet, C. (2013), Hot-melt co-extrusion: requirements, 
challenges and opportunities for pharmaceutical applications. Journal of Pharmacy and 
Pharmacology 66 (2013) 167-179. 
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1. Introduction 
Co-extrusion is defined as the simultaneous hot-melt extrusion of two or more 
materials through the same die, creating a multilayered extrudate [1]. The technique allows to 
combine the desirable properties of multiple materials into a single structure with enhanced 
performance characteristics. The simultaneous extrusion of graphite and presswood for 
making pencils was already patented in the 19th century. Since 1940 hot-melt co-extrusion 
was utilized predominantly in the plastic industry and to a lesser extent in the food industry. 
Co-extrusion of plastics started with the production of pipes, wires and cables. The first major 
plastic co-extrusion was the production of the multilayer garden hose (patented in 1947). 
Another early example of plastic co-extrusion is the multilayer drinking straw, that came on 
the market in 1963 [2]. Plastic co-extrusion has a lot of applications in the packaging industry 
which can be divided into barrier and non-barrier applications. The incorporation of a barrier 
layer is used to control transmission of oxygen, carbon dioxide or moisture [3-5]. Non-barrier 
applications include improved appearance (coloration, opacity), improved sealing 
characteristics, stiffness/strength adjustment and printability. Around 1984 co-extrusion 
became popular in the food industry to produce snacks with different colors, textures or 
flavors. The outer material is usually starch- or cereal-based, while the filling can be cereal-, 
fat-, sugar- or water-based. In comparison to plastic co-extrusion, the use of food products has 
additional challenges. Due to many transformations (starch gelatinization, protein 
coagulation, formation of amylose-lipid complexes, non-enzymatic browning) occurring 
during co-extrusion-cooking, large rheological changes are observed, which complicates the 
process [6]. Moreover the shelf life of co-extruded food is often limited, because of migration 
of moisture or oil from the filling to the outer material [7]. 
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  Due to the advantages of hot-melt co-extrusion over conventional solid dosage form 
manufacturing techniques, the pharmaceutical industry became interested in this innovative 
technology. Besides the continuity of the process its major advantages are fewer processing 
steps, no use of organic solvents/water and the possibility of improving drug solubility or 
sustaining drug release [8-11]. Additional benefits of this technique include its versatility, 
increased throughput and reduced costs. By producing multilayer products with a reduced 
amount of expensive polymers and increased amount of inexpensive polymers a cost-efficient 
process can be achieved without sacrificing performance, e.g. by placing pigment only in 
appearance layers and/or by using recycled material in an inner layer [12]. The technology 
does have a price however. Besides the investment in equipment (additional extruders), there 
is often need for an experienced line operator (taken into account the increased levels of 
process complexity). In some cases the additional process costs may offset the material cost 
savings.  
Up until now co-extrusion has been barely applied in the pharmaceutical industry. The 
only two co-extruded dosage forms available on the market are Nuvaring®, a contraceptive 
vaginal ring, and Implanon®, a contraceptive implant [13]. So far, there are no co-extruded 
dosage forms for oral use on the market and only a few papers on this topic have been 
published during the last decade [1, 14-16].  
  
2. Process and Equipment 
Co-extrusion is the process of extruding two or more materials through a single die 
[17]. This technology requires the combination of at least two extruders in a single processing 
step. Each individual extruder provides a stream of material that is combined in the co-
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extrusion die connected to the outlet of the extruders. The co-extrusion equipment is 
fundamentally comprised of two or more feeders, extruders and a co-extrusion die (Fig. 1). 
Screw extruders are typically used for pharmaceutical purposes which are available in several 
types that differ from one another in number of screws (single or twin), rotational direction of 
the screws (co- or counterrotating) and whether or not the screws are intermeshing. Twin 
screw extrusion has several advantages over single screw. It offers intense mixing of the 
components as it imparts both dispersive and distributive mixing. The two screws create an 
environment of controlled temperature and pressure inside the extrusion barrel. Co-rotating 
intermeshing twin screw extruders are primarily used in pharmaceutical manufacturing since 
they provide intensive mixing, a relatively short residence time and ensure complete emptying 
of the extruder (minimizing loss of highly valuable product). Each extruder of a co-extrusion 
setting is typically divided into three sections for feeding, compression and metering of the 
materials. Materials are introduced via the feeding section from where they are transported to 
the compression section. In the compression section, materials are softened, homogenized and 
compressed. Finally, the material enters the metering section, where the pulsating flow is 
reduced to ensure a uniform delivery rate through the die. 
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Figure 1. Schematic image of a co-extrusion equipment: 1) feeder; 2) extruder; 3) die. 
 
 In co-extrusion the die design is as critical as the selection of the materials and 
optimum processing conditions to provide uniform layer distribution and thickness in the co-
extruded formulation. There are two systems to combine melt streams from the individual 
extruders: single manifold dies or multimanifold dies (Fig. 2). In single manifold dies, the 
different melt streams flow together through the same manifold. Prior to the die, the incoming 
melts form the different extruders are arranged in the proper sequence and their velocities are 
balanced by feedblocks. Multimanifold dies exhibit individual manifolds for each layer, 
which means the different melts are only combined near the die exit. Each manifold is 
designed to distribute its melt to the desired shape and location in the structure, before 
combining with the other melt streams [12]. Besides the number of manifolds, dies can also 
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be classified according to their shape. Flat dies are utilized for the production of films and 
patches, whereas e.g. circular dies are used for pelletization. 
 
 
Figure 2. Schematic representation of a multimanifold die (left) and a single-manifold die 
(right). 
 
  After the co-extrudate has exited the die, it can be further processed into its final 
dosage form. Several downstream solutions are available for shaping (co-)extrudates into 
dosage forms such as calendaring, (co-)injection moulding and pelletizing. A major challenge 
at the moment is to shape the final product in a continuous way. Calendering is the process 
where a co-extrudate is passed through two temperature-controlled rolls, which contain tablet- 
or pill-shaped cavities. This technique offers an optimization towards continuous processing 
by allowing final shaping of the extrudates immediately after exiting the die. During injection 
moulding, the extruded mass is injected into a mould at high pressure. After cooling down, 
the product is removed from the mould. Pelletizing is another downstream solution. Note that 
traditional pelletizers that consist of blades on a helical rotor cannot be used for shaping (co-
)extrudates, since deformed pellets would be yielded due to the softness of the extruded mass. 
Die face cutters are available post-extrusion for the production of spheronized micropellets 
[18].  
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3. Materials used in hot-melt co-extrusion  
  Proper material selection is critical to produce good quality co-extruded dosage 
forms. Co-extruded dosage forms are multilayer systems of which each layer consists of a 
mixture of one or more active pharmaceutical ingredients and functional excipients, such as 
matrix carriers, plasticizers and other processing aids (antioxidants, bulking agents, release 
modifying agents). Matrix carriers need to soften easily inside the barrel of the extruder and 
solidify quickly after exiting the die. The selection of appropriate carriers is important in the 
formulation and design of a hot-melt (co-)extruded dosage form. The carrier material 
properties often dictate the processing conditions necessary for the production of the dosage 
form. Generally, thermoplastic polymers exhibiting a low glass transition temperature or 
melting point are used. If the drug does not exhibit plasticizing properties, the use of 
polymeric carriers may require the incorporation of a plasticizer into the formulation in order 
to improve the processing conditions, the stability or the physico-mechanical properties of the 
final product. Depending on the properties of the drug substance and the other excipients in 
the formulation, the drug can be present as crystals (crystalline suspension), in amorphous 
state (glassy suspension) or molecularly dispersed in the carrier (solid solution) [11]. The state 
of the drug in the final dosage form influences the processability and the stability of the 
product.   
 Since melt extrusion is an anhydrous process, potential drug degradation from 
hydrolysis is avoided. In addition, poorly compactible drugs can be incorporated into solid 
dosage forms. Nevertheless materials used in hot-melt (co-)extrusion must meet the same 
level of purity and safety as those used in traditional dosage forms, meeting the strict 
regulatory requirements e.g. Generally Recognized As Safe status (GRAS), Good 
Manufacturing Practice (GMP) and Environmental, Health and Safety (EHS) guidelines. 
Hot-melt co-extrusion: requirements, challenges and 
opportunities for pharmaceutical applications INTRODUCTION 
 
13 
 
Furthermore, in addition to acceptable physical and chemical stability, these materials must 
possess a certain degree of thermal stability, although this has to be put into perspective since 
Repka et al. showed that a thermally non-stable drug, hydrocortisone, could be successfully 
incorporated into hydroxypropylcellulose films by hot-melt extrusion [19]. 
In comparison to conventional hot-melt extrusion (HME), development of a co-
extruded formulation is more challenging as additional technical considerations have to be 
taken into account when selecting polymer combinations. A successful co-extrusion process 
requires that the polymer melts can be processed at similar temperatures because they need to 
flow through the co-extrusion die under the same temperature conditions. Although both 
melts may be extruded at different temperature conditions in each barrel, each temperature 
profile needs to allow the melt to exit the co-extrusion die at the set die temperature. 
Furthermore, melt viscosity matching and adequate adhesion between the layers are 
indispensable to ensure the quality of co-extruded dosage forms. 
 
3.1. Viscosity matching 
Layer non-uniformity is an often faced problem in polymer co-extrusion and can be 
caused by many process factors such as melt temperature non-uniformity, pressure variations 
and velocity mismatch. However the key for success is the adequate choice of materials in 
order to match the melt viscosities of the layers. Viscosity matching is not always easy as 
each polymer has its own viscoelastic properties and each layer is, depending on its location 
in the structure, exposed to different shear rates during the co-extrusion process. As polymer 
viscosity is dependent on shear and temperature it is logical that melt temperature uniformity 
is essential to control temperature-related viscosity. 
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Viscosity mismatch can cause encapsulation and interfacial instability. Encapsulation  
happens when a low-viscosity melt flows around a high-viscosity melt and encapsulates it. 
The polymer viscosity ratio determines the degree of encapsulation: the larger the difference 
in viscosity, the higher the risk for encapsulation. Viscosity mismatch can also lead to 
interfacial instabilities (Fig. 3a) such as zigzag or wave patterns. If the layers are combined in 
a feedblock and then pass a single manifold die there is a longer contact zone inside the die 
and more time for the layers to relocate and cause encapsulation or instability. Multimanifold 
dies on the other hand can allow for a larger mismatch in polymer viscosities because the 
layers are only combined near the die exit. However, when feedblock technology is being 
used and known viscosity differences are present, modifications can be made to the feedblock 
geometry to correct for the viscosity mismatch using movable vanes and/or distribution pins 
[12]. 
 Viscosity of thermoplastic polymers is generally assessed via melt flow index (MFI) 
measurements. The melt flow index is a measure of the ease of flow of the melt of a 
thermoplastic polymer and is defined as the weight of the polymer extruded per time unit 
through a capillary of specific diameter and length in a melt flow indexer by pressure applied 
through dead weight under prescribed temperature conditions as specified by ASTM  D1238 
[20]. MFI is inversely proportional to apparent melt viscosity. By performing measurements 
at different temperature and shear conditions, the viscosity of each polymer at specific 
conditions can be predicted. 
 Yet in case the viscosities are perfectly matched, layer rearrangement can still occur. 
This phenomenon is caused by secondary flows normal to the primary flow direction as a 
result of the viscoelastic characteristics of the polymer. The amount of layer rearrangement 
depends on the viscoelastic properties of the material and on the die geometry. Layer 
Hot-melt co-extrusion: requirements, challenges and 
opportunities for pharmaceutical applications INTRODUCTION 
 
15 
 
rearrangement increases with increasing viscoelastic characteristics. With respect to the die 
geometry, interface deformations occur in square and rectangular dies, while they are less 
likely to happen in circular dies. Differences in normal forces in non-radially symmetrical 
channels cause secondary flows, which produce recirculation zones followed by layer 
rearrangement. [21, 22]. Accordingly, viscoelastic flow effects can be minimized by adequate 
selection of the polymers and die geometry. 
 
 
Figure 3. Typical co-extrusion problems: A) Interfacial instability; B) poor adhesion. 
 
3.2. Adhesion 
A common problem for all layered products is adhesion control. Yet adequate 
adhesion between the layers is essential to avoid separation during downstream processing 
(Fig. 3b). Adhesion is defined as the tendency of dissimilar particles or surfaces to cling to 
one another or as the molecular attraction that holds the surfaces of two dissimilar substances 
together [23]. The adhesion between polymers has been widely studied over the last two 
decades.  
The recent adhesion literature divides adhesion mechanisms into three main 
categories: mechanical interlocking, molecular bonding, and thermodynamic adhesion [24]. 
The mechanical coupling adhesion mechanism (Fig. 4a) is based on a “lock and key” effect: 
the material of one layer interlocks into the irregularities of the surface of the other layer. A 
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second mechanism for explaining the adhesion between two surfaces in close contact is 
molecular bonding (Fig. 4b). It occurs when surface atoms of two separate surfaces can 
interact via dipole-dipole interactions, van der Waals forces and chemical interactions (i.e. 
ionic, covalent and metallic bonding). Chemical bonding can also occur following the 
formation of new compounds at the interface, which is known as reaction bonding. The third 
category, thermodynamic adhesion (Fig. 4c), implies that the thermodynamics of the polymer 
system will attempt to minimize the surface free energy. The advantage of the thermodynamic 
mechanism over the other mechanisms is that it does not require molecular interaction for 
good adhesion, only an equilibrium process at the interface [25]. 
 
 
Figure 4. Adhesion mechanisms: A) mechanical interlocking; B) molecular bonding; C) 
thermodynamic adhesion. 
 
Polymer compatibility influences adhesion but is not a prerequisite for adhesion. 
Miscible polymers will diffuse into each other at the interface, creating an interphase, by one 
of the mechanisms described above, while adhesion between immiscible polymers is 
generally weak due to limited interdiffusion. Many polymer combinations used in co-
extrusion are immiscible systems. Fairly often tie layers are used which are functionalized 
resins that are bond to adjacent polar and non-polar resins. There are also various process 
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variables affecting adhesion in co-extrusion. For example, increasing the temperature and 
contact time usually increases adhesion since there is a longer time for the chemical reaction 
and chain entanglement to occur. On the other hand adhesion is decreased by high interfacial 
stress and shrinkage of one of the layers. 
Generally, adhesion is quantified with a destructive test to evaluate the ability of an 
interface to resist mechanical stress. The testing methods can be divided into tensile, shear, 
cleavage and peel tests [26]. Tensile and shear adhesion testing methods measure the load or 
stress required to fail a standard junction. The main advantage of these stress-based tests is 
that they are simple to perform and the calculation of the stress is straightforward. Therefore, 
this type of adhesion testing method is most widely used. There are also a whole class of 
testing methods based on resistance to cleavage. These tests involve forcing a wedge at the 
interface, thereby creating cleavage stresses. During a peel test, a coating is pulled from its 
substrate. The crack propagates in a stable manner at the peel speed. The force required to 
continue cracking is monitored as a function of crack position and time. A drawback of the 
adhesion testing methods is that failure happens suddenly and can occur at the interface or 
within one of the layers, meaning that it is not always adhesion which is measured.  
 
3.3. Other considerations 
 Interdiffusion of the layers should be considered. If the two adjacent layers are 
miscible, drug and/or polymer of one layer can diffuse into the other layer. It is most likely to 
happen using a single manifold die because the melt streams have more time to interact. In 
order to prevent delamination of the co-extruded structure, the shrinkage of the polymers also 
needs to be taken into account. Delamination occurs when the shrinkage of both layers differs 
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too much. Considering for example a co-extruded tube consisting of two concentric layers. If 
the shrinkage percentage of the inner layer is more than that of the outer layer, a gap will form 
between the two layers. If the outer layer is brittle and shrinks more than the inner layer it 
might burst or in case the outer layer is stretchable, it might tighten around the inner layers 
and a delamination-free structure may be achieved [27]. 
 Given that carriers used in co-extruded dosage forms need to be thermoplastic and 
meet the regulatory requirements (GRAS, GMP and EHS) and taking into account the extra 
considerations (viscosity, adhesion, miscibility, shrinkage) for combination of polymers, it is 
obvious that polymer selection for co-extrusion is not always straightforward. There is a need 
for new polymers to improve the polymer variety in order to facilitate the choice of polymers 
in a co-extruded dosage form. 
 
4. Pharmaceutical Applications  
The development of fixed-dose combinations is becoming increasingly important from 
a public health perspective. Not only do they improve patient adherence, they can also have a 
better efficacy, a reduced incidence of adverse effects and/or less development of resistance 
(in the case of antimicrobials). Additionally there can be economical benefits such as lower 
manufacturing costs and simpler logistics of distribution. Such “polypills” are being used in 
the treatment of e.g. cardiovascular disease, diabetes, hyperlipidemia, HIV, tuberculosis and 
malaria. An innovative way to produce fixed-dose combinations is via hot-melt co-extrusion. 
Depending on the type and concentration of the carriers used in the different layers, fixed-
dose combination products with different release rate of both drugs can be designed. A well-
known application is the combination of a beta-blocker and a diuretic for the treatment of 
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cardiovascular disease [28]. Furthermore, co-extruded dosage forms offer the opportunity to 
modulate the release profile of a specific drug by incorporating the same drug in layers 
formulated with different carriers. This way, it is possible to develop controlled release 
formulations with a fast onset of action. Co-extrusion further allows to formulate 
incompatible drugs in different layers, enabling their simultaneous administration. A well-
known example of incompatible drugs which are concurrently used is isoniazid and 
rifampicin for the treatment of tuberculosis.  
Despite the versatility of co-extrusion as manufacturing technique for pharmaceutical 
dosage forms, only a few applications exist to date. Table 1 gives an overview of the current 
pharmaceutical applications of hot-melt co-extrusion. Until now only two of these co-
extruded dosage forms are commercially available i.e. Nuvaring® and Implanon®. Nuvaring® 
(MSD) is a contraceptive intravaginal ring that releases etonogestrel and ethinyl estradiol over 
a period of 21 days. Implanon® (Schering-Plough) is a non-biodegradable flexible rod that 
contains etonogestrel and provides contraceptive efficacy during a period of 3 years [29].  
Both dosage forms consist of a core (composed of ethylene vinylacetate copolymers) 
containing the drug(s), surrounded by an outer layer (also composed of ethylene vinylacetate 
copolymers) that regulates drug release.  
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Table 1. Overview and composition of pharmaceutical products manufactured via hot-melt 
co-extrusion. 
Dosage 
form 
Layer 1  Layer 2 Ref. 
Drug Carrier  Drug Carrier   
Oral theophylline soy protein isolate  - soy protein isolate [14] 
 theophylline/ 
acetaminophen 
polyethylene 
glycol 
 theophylline/ 
acetaminophen/  
no drug 
stearic acid [15] 
 theophylline polyethylene 
glycol 
 theophylline microcrystalline 
wax 
[1] 
 metoprolol tartrate ethylcellulose  hydrochlorothiazide polyethylene oxide [16] 
 troglitazone povidone  - ethylcellulose [30] 
 CI-1017 povidone  -  Eudragit® RS PO [30] 
 perindopril    
tert-butylamine salt 
Eudragit® E 100  - Eudragit® RL PO [31] 
 naltrexone HCl Eudragit® RS PO  - Eudragit® RS PO [32] 
       
Implant etonogestrel ethylene vinyl 
acetate (28% 
vinyl acetate) 
 - ethylene vinyl 
acetate (14% 
vinyl acetate) 
[13] 
 flucinolone 
acetonide 
polycaprolactone/ 
polyvinyl acetate 
 - poly(lactic-co-
glycolic acid)/ 
ethylene vinyl 
acetate 
[33] 
 macrocyclic lactone ethylene vinyl 
acetate (28% 
vinyl acetate) 
 - ethylene vinyl 
acetate (28%  
vinyl acetate) 
[34] 
       
Vaginal  
ring 
etonogestrel + 
ethinyl estradiol 
ethylene vinyl 
acetate (28% 
vinyl acetate) 
 - ethylene vinyl 
acetate (9%  
vinyl acetate) 
[35] 
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Co-extrusion is gaining importance in the production of oral drug products. So far, 
there are no co-extruded dosage forms for oral use on the market, but several research studies 
have already been done in this field. Quintavalle et al. characterized hot melt co-extruded 
cylindrical systems for controlled drug delivery. The sustained release profile was obtained by 
extruding two concentric theophylline-loaded matrices: an inner hydrophilic polyethylene 
glycol-based matrix combined with an outer lipophilic layer, mainly consisting of 
microcrystalline wax. A screening of several devices, differing in dimensions and relative 
proportions of inner and outer part was performed based on the in vitro drug release. The 
release mechanisms were studied with the use of a mathematical model [1, 15]. Vaz et al. 
produced double-layer delivery devices based on soy protein derived materials via co-
injection moulding. Layer thickness uniformity was influenced by the viscosity ratio between 
core and coat materials. Through adequate material selection and the optimization of the 
processing conditions an accurate control of the relative thickness of the layers of the device 
was possible. The preliminary data demonstrated the potential of these systems to achieve a 
controlled drug delivery. [14]. A recent study by Vynckier et al. [16] described the successful 
preparation of fixed-dose combination mini-matrices with metoprolol tartrate embedded in a 
matrix core offering a range of controlled release profiles and hydrochlorothiazide 
incorporated in an immediate release coat. The influence of adjusting the concentration of 
polyethylene oxide as a hydrophilic component or changing the drug load in the plasticized 
ethylcellulose matrix was studied.   
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5. View to the future  
 Today’s drug development challenges have tremendously increased. Over the last 
years the economy has played a role in many pharmaceutical products to be sidelined. 
Pharmaceutical production processes need to gain efficiency and versatility while new drug 
substances are more difficult to process because their bioavailability is often poor. Enhancing 
bioavailability of poorly water soluble drugs and moving from batch toward continuous 
processing are ever increasing topics in academia and pharmaceutical companies. As hot-melt 
(co-)extrusion allows the continuous production of a variety of dosage forms while offering 
the possibility to enhance the solubility of poorly water soluble drugs, this drug formulation 
technique provides the perfect answer to some of today’s biggest challenges. 
Hot-melt (co)-extrusion is a very promising innovative method to produce drug 
delivery systems. Co-extrusion provides manufacturers with a process that increases 
throughput, reduces manufacturing costs and supplies versatility for dosage forms. 
Furthermore, this technique presents great potential for the continuous production of fixed-
dose combination products which are gaining importance in pharmaceutical industry.  
 However, the amount of marketed (co-)extruded drug products is still small. To our 
opinion the major barriers to the implementation of co-extrusion in the pharmaceutical 
industry are the conservative attitude of the pharmaceutical companies (the fear to change), 
the significant investment initially required and the lack of process knowledge. Other 
impediments are the limited number of thermoplastic polymers available and the elaborate 
method to predict a suitable carrier for a specific drug. The traditional approach used in 
carrier selection involves the manufacturing and characterization of numerous candidate 
formulations. The cost and time constraint of this empirical approach makes it unattractive. 
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Regardless of these hurdles, hot-melt extrusion has already achieved a strong place in 
the pharmaceutical industry and its use is steadily increasing. Successful products have been 
marketed (e.g. Kaletra® and Norvir®, Abbott Laboratories, USA) and many others are in the 
pipeline. Moreover an increasing number of formulations are being investigated within 
academia and pharmaceutical companies. Rapid screening tools are being developed to 
shorten the empirical screening time and thus reduce the corresponding costs. Process 
engineers and formulation scientists are cooperating in order to enhance the technology. New 
thermoplastic polymers are being designed, specifically for HME applications (e.g. Soluplus®, 
BASF, Germany). These facts prove that HME will become commonplace within the 
pharmaceutical industry in the near future. A logical next step would be the breakthrough for 
co-extrusion. For companies that have already invested in HME equipment, it would only be a 
small step towards co-extrusion. A limited extra investment cost would broaden the scope of 
dosage forms that can be manufactured. In conclusion, hot-melt co-extrusion is a versatile 
manufacturing technique for drug delivery systems and it will most likely face an exciting 
future within the pharmaceutical industry. 
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1. Introduction 
Proper material selection is critical in order to produce high quality co-extruded 
dosage forms. Some of the basic requirements for polymers used in hot-melt co-extrusion are 
that the polymers must exhibit thermoplastic characteristics (soften easily inside the barrel of 
the extruder and solidify quickly after exiting the die) and that they must possess a certain 
degree of thermal stability. Extrudability of a polymer is mainly determined by its glass 
transition (Tg) or melting temperature (Tm) and its melt viscosity. As a general rule of thumb, 
an extrusion process is run at a temperature of 10 or 50 °C above Tm or Tg, respectively [1]. 
Accordingly, polymers exhibiting a high Tg or Tm require a higher processing temperature 
increasing the risk of drug degradation during hot-melt extrusion. Moreover, polymers with a 
high molecular weight exhibit high melt viscosity and are difficult to extrude. Other relevant 
characteristics are a low hygroscopicity in order to ensure the stability of the formulation (e.g. 
prevent the risk of recrystallization of solubilized drugs) and no toxicity since relatively large 
amounts of polymer will be administered. Besides these basic requirements, some 
pharmaceutical aspects and technical considerations need to be taken into account. 
Pharmaceutical aspects include e.g. the drug release characteristics as hydrophilic polymers 
tend to release drugs in an immediate release manner, while hydrophobic polymers are 
expected to provide sustained drug release. Technical considerations include that co-extruded 
polymers need to have similar extrusion temperature and melt viscosity while adequate 
adhesion between the layers is also essential. 
Accordingly preliminary polymer characterization is indispensable. This chapter 
focuses on the polymer characteristics relevant for hot-melt co-extrusion. These include 
solubility, hygroscopicity, toxicity, thermal stability, melt viscosity and extrudability. As 
adhesion, interdiffusion and delamination depend on specific polymer combinations as well as 
on the model drugs embedded, these properties are not considered in this chapter. 
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2. Materials and methods 
2.1. Materials 
The polymers tested were: Ethocel® std 10 (ethylcellulose, DOW Chemical Company, 
Midland, USA), Eudragit® E and RS PO (Evonik, Darmstadt, Germany), Kollidon® 30, VA 
and SR (BASF, Ludwigshafen, Germany), SentryTM Polyox® WSR N10 (polyethylene oxide 
(MW: 100,000 g/mol), Colorcon, Dartford Kent, United Kingdom), Soluplus® (BASF, 
Ludwigshafen, Germany) and CAPA® 6506 (polycaprolactone (MW: 50,000 g/mol), 
Perstorp, Warrington, United Kingdom). 
 
2.1.1. Ethylcellulose (Ethocel®)  
Ethylcellulose (Fig. 1), an ethylether of cellulose, is a long-chain polymer of ß-
anhydroglucose units. The number of monomeric units can vary to provide a wide variety of 
molecular weights. Viscosity increases with increasing chain length. It is a nonionic, non-
hygroscopic, physiologically inert polymer that is practically insoluble in water. 
Ethylcellulose is widely used in oral and topical pharmaceutical formulations. Its main use in 
oral formulations is as a hydrophobic coating agent or matrix former to modify drug release, 
to improve the stability of a formulation (e.g. inhibit oxidation) and for taste masking. 
Ethylcellulose is GRAS listed and included in the FDA (Food and Drug Administration) 
inactive ingredients guide [2]. In our study, Ethocel® std 10 with an ethoxyl content of 48.0-
49.5% w/w and a respective viscosity of 9-11 mPa.s (5% solution (w/v) in 80:20 
toluene:ethanol, measured at 25°C) is applied as sustained-release agent. 
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Figure 1: Chemical structure of ethylcellulose. 
 
2.1.2. Polymethacrylates (Eudragit® E and RS PO) 
Polymethacrylate polymers are primarily used as coating agents for oral capsule and 
tablet formulations. Depending on the type of polymer used, films with different solubility 
characteristics can be produced. Polymethacrylates are also used in direct-compression, as 
binders in wet-granulation processes and as matrix formers in oral formulations. They are 
included in the FDA inactive ingredients guide [2]. 
Eudragit® E PO (Fig. 2) is a cationic copolymer based on dimethylaminoethyl 
methacrylate, butyl methacrylate and methyl methacrylate in a ratio of 2:1:1. The polymer has 
a weight average molar mass of approximately 47,000 g/mol. Eudragit® E PO is soluble in 
gastric fluid and acidic solutions up to pH 5 and swellable/permeable above pH 5.0.  In our 
study, it is applied as immediate-release agent. 
 
Figure 2: Chemical structure of Eudragit® E PO. 
Physico-chemical polymer characterization for co-extrusion CHAPTER 1 
 
34 
 
Eudragit® RS PO (Fig. 3) is a cationic copolymer based on ethyl acrylate, methyl 
methacrylate and trimethylammonioethyl methacrylate chloride (1:2:0.1), with an average 
molecular weight of approximately 32,000 g/mol. Eudragit® RS PO is water-insoluble, but 
water-permeable with a pH-independent permeability which makes it suitable for the 
formulation of sustained-release dosage forms. Due to their cationic properties, Eudragit® E 
and RS PO can only be used in combination with nonionic and cationic drugs. 
 
 
Figure 3: Chemical structure of Eudragit® RS PO. 
 
2.1.3.  Polyvinylpyrrolidone (Kollidon®) and copolymers (Kollidon® VA 64 and SR) 
Polyvinylpyrrolidone, also known as povidone, is a synthetic polymer consisting of 
linear 1-vinyl-2-pyrrolidinone groups (Fig. 4). Different degrees of polymerization result in 
polymers with various molecular weights. Kollidon® 30 has a molecular weight of 50,000 
g/mol. Povidone has been widely used in solid dosage forms as tablet binder, drug carrier and 
coating agent. It is a very hygroscopic polymer that can absorb significant amounts of 
moisture even at low relative humidity. Polyvinylpyrrolidone is readily water soluble, 
therefore it is intended to be used for immediate release formulations [2, 3]. 
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Figure 4: Chemical structure of Kollidon® 30. 
 
Copovidone (Kollidon® VA 64, Fig. 5) is an amorphous copolymer manufactured 
from vinylpyrrolidone and vinyl acetate monomers. The average molecular weight of the 
polyvinylpyrrolidone and the polyvinyl acetate part is about 450,000 and 50,000 g/mol, 
respectively. Vinylpyrrolidone is a hydrophilic and water-soluble monomer whereas the vinyl 
acetate monomer is lipophilic and water-insoluble. The monomer ratio (6:4) is balanced in a 
way that the polymer is still freely soluble. Thus the release profile of formulations composed 
of this polymer is mostly instant release. Copovidone is used in the pharmaceutical industry as 
a tablet binder, coating agent or matrix former. It is less hygroscopic than PVP [2, 3]. 
 
 
Figure 5: Chemical structure of Kollidon® VA 64 and SR. 
 
 Kollidon® SR is a spray-formulated mixture of polyvinylpyrrolidone and polyvinyl 
acetate in a ratio of 2:8. Due to the large amount of the water-insoluble vinyl acetate 
monomer, Kollidon® SR is water-insoluble and therefore used for sustained drug delivery. 
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Kollidon® SR contains no ionic groups and is therefore inert to drug substances. The 
sustained-release properties are unaffected by ions or salts. The water uptake is much less 
than that of povidone or copovidone [2, 3]. Polyvinylpyrrolidone and its copolymers are 
generally regarded as nontoxic and included in the FDA inactive ingredients guide. 
 
2.1.4.  Polyethylene oxide (SentryTM Polyox®) 
Polyethylene oxide (PEO) (Fig. 6) is a nonionic, water-soluble homopolymer of 
ethylene oxide. It is available in a broad range of molecular weights, i.e. from 100,000 up to 
8,000,000 g/mol. Polyox® WSR N10 has a molecular weight of 100,000 g/mol. Low 
molecular weight PEO is suitable for immediate release formulations. High molecular weight 
PEO has been successfully applied in sustained-release dosage forms due to its swelling 
properties. As the swelling properties depend on the molecular weight, modification of the 
release profile is possible by choosing the appropriate PEO grade. PEO exhibits low 
hygroscopicity, resulting in a low moisture content < 1%. Polyethylene oxides are used as 
tablet binder in direct compression, in hot-melt produced dosage forms and in other drug 
delivery systems. They are included in the FDA inactive ingredients guide. 
.  
 
Figure 6: Chemical structure of polyethylene oxide. 
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2.1.5.  Polyethylene glycol – polyvinyl caprolactam – polyvinyl acetate graft copolymer 
(Soluplus®) 
Polyethylene glycol – polyvinyl caprolactam – polyvinyl acetate graft copolymer (Fig. 
7) is a polymeric solubilizer with an amphiphilic chemical structure. The hydrophilic 
backbone of the polymer consists of polyethylene glycol (molecular weight 6,000 g/mol); the 
side chains consisting of vinyl acetate randomly copolymerized with vinyl caprolactam are 
lipophilic. Hence, Soluplus® forms micelles in aqueous solution above the critical micelle 
concentration (7.6 mg/l). The average molecular weight of Soluplus® is in the range of 90,000 
to 140,000 g/mol. Soluplus® was designed to serve as a matrix for solid glassy solutions and 
to solubilize poorly water soluble drugs in aqueous media. According to BASF, Soluplus® has 
been tested over the full range of toxicological studies [3]. 
 
 
Figure 7: Chemical structure of polyethylene glycol–polyvinyl caprolactam–polyvinyl 
acetate grafted copolymer. 
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2.1.6. Polycaprolactone (CAPA®) 
Polycaprolactone (Fig. 8) is a biodegradable, biocompatible polyester derived from ε-
caprolactone. The number average molecular weight can vary from 3,000 to 80,000 g/mol. 
CAPA® 6506 is a high molecular weight (50,000 g/mol) linear polyester. Due to its 
hydrophobic character and a high permeability to many drugs, polycaprolactone is suitable for 
controlled drug delivery. It has been approved by the FDA in specific applications used in the 
human body as e.g. drug delivery device, suture or adhesion barrier.  
 
 
Figure 8: Chemical structure of polycaprolactone. 
 
 
2.2. Thermogravimetric analysis (TGA) 
A thermogravimetric analyser (Hi-res TGA 2950, TA instruments, Leatherhead, UK) 
was employed to investigate the thermal stability of the pure polymers. Samples (±15 mg) 
were equilibrated at 50 °C and heated to 500 °C at a heating rate of 10 °C/min while recording 
the weight loss.  
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2.3. Differential scanning calorimetry  
Glass transition temperature (Tg) and/or melting point (Tm) of pure components were 
analyzed by differential scanning calorimetry (DSC) using a Q2000 DSC (TA Instruments, 
Leatherhead, UK). The system was equipped with a refrigerated cooling system. Samples 
(±10 mg) were run in hermetically sealed aluminum pans. Depending on the samples and the 
determined parameters, the experimental method consisted of a single heating cycle (heating 
rate of 10 °C/min) or a three-phase analysis with consecutive heating, cooling and heating 
cycles. All results were analyzed using the TA Instruments Universal Analysis 2000 software. 
 
2.4. Melt flow index determination 
The basic property measured by the melt flow test was the melt viscosity of the 
polymer at a particular shear stress (related to the applied load) and temperature. Melt flow 
index (MFI) was determined by means of a MPX 62.92 melt flow indexer (Göttfert, 
Germany) according the ISO 1133 standard (Fig.9). A die with a diameter of 2.095 mm was 
used. Different loads (1.20, 2.16, 3.80, 5, 10, 12.5, 15 and 21.6 kg) were applied 
(corresponding to shear stresses of 11148, 20066, 35302, 46450, 92900, 116125, 139350 and 
200664 Pa).  Polymers were manually fed into a barrel and after manual compression of the 
material to remove air, the powder mixture was preheated for 360 seconds. The amount of 
polymer extruded in 10 min was measured, expressed in units of cm3/10 min. This value (the 
MFI) was then converted to shear rate (s-1) and melt viscosity (Pa.s). Measurements were 
performed at the lowest possible temperature allowing flow through the die channel and at 
higher temperatures if applicable. 
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Figure 9: Schematic of a melt flow indexer. 
 
2.5. Hot-melt extrusion 
All thermoplastic polymers were hot-melt extruded using a Prism Eurolab 16 co-
rotating, fully intermeshing twin screw extruder (ThermoFisher Scientific, Germany). The 
extrusion temperature varied according to the polymer, but all five heating segments of the 
extruder were set at the same temperature. The appropriate extrusion temperature was defined 
as the lowest temperature at which the extruder torque was below 80% motor load. A strand 
die with a diameter of 3 mm was mounted at the end of the extruder. The machine was 
equipped with a gravimetric Brabender powder feeder (Duisburg, Germany). The screw speed 
and feed rate were kept constant at 60 rpm and 250 g/h.   
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3. Results 
3.1. Thermal analysis 
As polymers must be thermally stable at least at the extrusion temperature employed, 
thermal decomposition was studied using thermogravimetric analysis. Glass transition and 
melting temperatures of the polymers were determined with DSC. The DSC and TGA results 
are summarized in Fig. 10. Following polymers were pure amorphous as they exhibited no 
melting, but one (or more) glass transition temperature(s): Ethocel® std 10, Eudragit® E and 
RS PO, Kollidon® 30, VA and SR and Soluplus®. The presence of both a glass transition and 
a melting temperature for Polyox® WSR N10 and CAPA® 6506 indicated they were semi-
crystalline polymers.  
 
Figure 10. Comparison of Tg or Tm (by DSC) with degradation temperature (by TGA) of pure 
polymers. 
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As mentioned in the introduction, it is estimated that thermoplastic polymers can be 
extruded at a temperature of 10 or 50 °C above their Tm or Tg, respectively [1]. Thus, the 
difference between Tm + 10 °C or Tg + 50 °C and the degradation temperature serves as a first 
indication of the extrusion temperature range. Within the extrusion temperature range, 
extrusion can be performed from a process and polymer stability point of view. Kollidon® 30 
showed a glass transition and degradation temperature around 149 and 200 °C, respectively. 
The small difference between the Tg and decomposition temperature limits its application as 
pure polymer for HME. Kollidon® SR showed two glass transitions at 37 and 151 °C, 
respectively. Although pure Kollidon® SR showed no decomposition on TGA below 260 °C, 
estimation of the extrusion range was difficult due the existence of two Tg’s. For all other 
polymers the estimated extrusion temperature ranges were relatively broad (≥50 °C): Ethocel
® 
std 10 (183-260 °C), Eudragit® E PO (98-240 °C), Eudragit® RS PO (115-170 °C), Kollidon® 
VA (153-255 °C), Soluplus® (120-275 °C), Polyox® WSR N10 (79-300 °C), CAPA® 6506 
(70-300 °C).  
Besides the width of the extrusion temperature range, the lower limit is also important. 
In pharmaceutical HME applications, it is advisable not to exceed a process temperature of 
150 °C, in order to guarantee the stability of the active pharmaceutical ingredient. In this 
manner, materials with a high Tg/Tm can only be extruded within a small temperature range 
irrespective of their degradation temperature. In spite of the broad extrusion temperature 
range of Ethocel® std 10, in pharmaceutical applications the use of a plasticizer is mandatory 
(due to its high Tg). On the contrary, high thermal stability combined with a relative low 
Tg/Tm, provides a broad (estimated) range for pharmaceutical extrusion of Eudragit® E PO 
(98-150 °C), Eudragit® RS PO (115-150 °C) and Soluplus® (120-150 °C), Polyox® WSR N10 
(79-150 °C), CAPA® 6506 (70-150 °C). Besides, the low Tm of Polyox® WSR N10 and 
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CAPA® 6506 allows extrusion at low temperature which makes them suitable carriers for 
thermolabile drugs. 
 
3.2. Melt viscosity 
Besides the glass transition and the melting temperature, melt viscosity is another 
crucial factor determining extrudability. Polymer melt viscosity should be low enough to 
enable flow through the extrusion channel. At the same time it should be high enough to avoid 
problems during downstream processing. The measurement of MFI is a convenient method 
for estimating the flow behavior of polymer melts. Because of its simplicity and the relatively 
low cost of the equipment, it is widely used for polymer processing control. It provides 
information about the ease of processing of polymers at different temperatures and shear 
rates. Accordingly, MFI measurements can be helpful in predicting the appropriate extrusion 
temperature. Besides, viscosity matching is indispensable for co-extrusion with a single 
manifold die as viscosity mismatch can cause interfacial instability and non-uniformity of the 
layer thickness.  
The influence of shear and temperature on the melt viscosity of the polymers is shown 
in Fig. 11. Melt viscosity is plotted versus shear rate for temperatures within the process 
temperature range of the pure polymers. Of all tested polymers, CAPA® 6506 required the 
lowest temperature (80 °C). Polyox® WSR N10 was processable from 120 °C, followed by 
the polymethacrylate polymers (130-150 °C), Soluplus® (140-150 °C), Ethocel® Std 10 (160 
°C) and Kollidon® 30 (190 °C). All polymers demonstrated shear thinning behavior which 
means that the viscosity reduces as a function of increasing shear stress. The influence of 
shear rate on melt viscosity was the biggest for Ethocel® Std 10 and Polyox® WSR N10 and 
the smallest for CAPA® 6506. Furthermore, all tested polymers showed a decrease in melt 
Physico-chemical polymer characterization for co-extrusion CHAPTER 1 
 
44 
 
viscosity with increasing temperature. In terms of viscosity, the polymethacrylates were more 
sensitive to temperature changes than all other tested polymers.  
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Figure 11. Melt viscosity of pure polymers as a function of shear rate at different 
temperatures: () 80 °C, () 90 °C, () 100 °C, () 110 °C, () 120 °C, (○) 130 °C, (◊) 140 
°C, (□) 150 °C, (▲) 160 °C, (▬) 190 °C. A: Ethocel® std 10, B: Eudragit® E PO, C: Kollidon® 
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VA (low) and Kollidon® SR (high), D: Soluplus®, E: CAPA® 6506, F: Eudragit® RS PO, G: 
Kollidon® 30 and H: Polyox® WSR N10. 
 
3.3. Extrusion temperature of pure polymers 
As mentioned in the general introduction, a successful co-extrusion process requires 
that the polymer melts can be processed at similar temperatures because they need to flow 
through the co-extrusion die under the same temperature conditions. Therefore, the pure 
polymers (without plasticizer) were hot-melt extruded and evaluated for processability. The 
extrudability was determined by various factors such as Tg or Tm, the melt viscosity, the 
power consumption of the extruder and the die pressure. The minimum extrusion temperature 
(Table 1) was defined as the lowest temperature at which the extruder torque and die pressure 
were below 80% motor load and 100 bar, respectively.  
 
Table 1. Glass transition, melting and minimum extrusion temperature of pure polymers. 
 Tg (°C) Tm (°C) Minimum extrusion temperature (°C) 
Ethocel® std 10 133 - - 
Eudragit® E PO 48 - 130 
Eudragit® RS PO 65 - - 
Kollidon® 30 149 - - 
Kollidon® VA 103 - 160 
Kollidon® SR 37 & 151 - 140 
Soluplus® 70 - 140 
Polyox® WSR N10 - 69 75 
CAPA® 6506 - 60 70 
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The semi-crystalline polymers CAPA® 6506 and Polyox® WSR N10 were already 
processable at a temperature of 70 and 75 °C, respectively. Extrusion at higher temperatures 
(120 °C) was also possible, still yielding adequate viscosity. With respect to CAPA® 6506, 
these results were in agreement with the MFI results. For Polyox® WSR N10 on the other 
hand, the minimum temperature required during the MFI measurements was not 
representative for the minimum extrusion temperature. This was explained by the additional 
shear in the extruder originating from the screws, taking into account the fact that the 
viscosity of Polyox® WSR N10 is strongly affected by shear. For the processing of pure 
Eudragit® E PO a temperature of at least 130 °C was required, irrespective of its low Tg (48 
°C). Pure Soluplus® and Kollidon® SR were extrudable at 140 °C, whereas Kollidon® VA 
required 160 °C. Despite its relatively low Tg (65 °C), extrusion of Eudragit® RS PO without 
plasticizer was impossible. The temperature required to extrude the pure polymer approached 
the degradation temperature (170 °C) of the polymer. Because of their high Tg (section 3.1) 
and viscosity (section 3.2), extrusion of Ethocel® Std 10 and Kollidon® 30 will also require 
plasticization.   
 
4. Conclusions 
Taking into account the Tg/Tm, the minimum extrusion temperature, the degradation 
temperature and the melt viscosity CAPA® 6506, Polyox® WSR N10 and Eudragit® E PO 
demonstrated good suitability for pharmaceutical hot-melt extrusion. Pure Soluplus® and 
Kollidon® SR also showed good extrudability, but within a narrow temperature range. 
Extrusion of Eudragit® RS PO without any plasticizer was not possible because the required 
temperature approached the degradation temperature of the polymer. Ethocel® std 10 and 
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Kollidon® 30 will require a plasticizer because of their high Tg, melt viscosity and a too small 
difference between Tg and degradation temperature in case of Kollidon® 30. 
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1. Introduction 
Multiparticulates are less dependent on gastric emptying rate, have a lower tendency 
for local irritation and have a reduced risk of dose dumping compared to monolithic dosage 
forms [1]. The greatest advantage of multiparticulate systems is the ease of dose adjustment 
without any formulation or process change. Because the dose can be adjusted by increasing or 
decreasing the number of individual particles in the dosage form, the surface area and 
consequently the drug release profile are not affected. This reduces the extra time and cost 
used for bioequivalence studies [2]. In addition, the use of fixed-dose combination (FDC) 
dosage forms is likely to increase in the future because they improve patient adherence [3]. A 
well-known application is the combination of a beta-blocker and a diuretic for the treatment 
of cardiovascular disease [4]. The aim of the present study was to evaluate the potential of co-
extrusion as manufacturing technique for the production of multiparticulate FDC dosage 
forms for oral application. Therefore, in this study hydrochlorothiazide (HCT, a diuretic) and 
metoprolol tartrate (MPT, a beta-blocker) were incorporated as immediate and sustained 
release model drugs, respectively. Via proper selection of polymers, a core/coat dosage form 
was developed via co-extrusion, the core providing sustained drug release (SR) and the coat 
immediate drug release (IR).  
  
2. Materials and methods 
2.1. Materials 
The polymers tested were: Soluplus® (BASF, Ludwigshafen, Germany), Eudragit® E 
and RS PO (Evonik, Darmstadt, Germany), Kollidon® VA and SR (BASF, Ludwigshafen, 
Germany), Ethocel® std 10 (ethylcellulose, DOW Chemical Company, Midland, USA), 
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SentryTM Polyox® WSR N10 (polyethylene oxide (PEO) (MW: 100,000 g/mol), Colorcon, 
Dartford Kent, United Kingdom), polyethylene glycol (PEG (MW: 4,000 g/mol), Fagron, 
Waregem, Belgium) and CAPA® 6506 (polycaprolactone (MW: 50,000 g/mol), Perstorp, 
Warrington, United Kingdom). Colloidal silicium dioxide (Fagron, Waregem, Belgium) was 
added to CAPA® to improve the flow properties. Pluronic® F68 (PLUR), triethyl citrate 
(TEC) and dibutyl sebacate (DBS) (Sigma-Aldrich, Bornem, Belgium) were used as 
plasticizers. Hydrochlorothiazide (HCT) (UTAG, Amsterdam, the Netherlands) and 
metoprolol tartrate (MPT) (Esteve Quimica, Barcelona, Spain) were incorporated as 
immediate release and sustained release model drugs, respectively. Their relevant physico-
chemical properties are listed in Table 1. All other chemicals were of analytical grade. 
 
Table 1. Physico-chemical properties of hydrochlorothiazide and metoprolol tartrate. 
Properties Structural formula 
Name hydrochlorothiazide  
 
Melting point  274 °C 
Degradation temperature 290 °C [5] 
Solubility in water very slightly soluble [6] 
pKa 7.9; 9.2 [7] 
   
Name metoprolol tartrate 
Melting point  124 °C 
Degradation temperature 160 °C [8] 
Solubility in water very soluble [6] 
pKa 9.6  
 
  
Co-extrusion as manufacturing technique for fixed-dose 
combination mini-matrices CHAPTER 2 
 
55 
 
2.1.1. Pluronic® F68 
PLUR is a nonionic polyoxyethylene–polyoxypropylene copolymer used in 
pharmaceutical formulations as emulsifying or solubilizing agent. The polyoxyethylene 
segment (80%) is hydrophilic while the polyoxypropylene segment (20%; MW: 1,800 g/mol) 
is hydrophobic. PLUR occurs as white, waxy, free-flowing granules with a melting point of 
52–57 °C. It is included in the FDA inactive ingredients guide. 
 
2.1.2. Triethyl citrate 
TEC is a water-soluble plasticizer prepared by esterification of citric acid and ethanol. 
It is a clear, oily and practically colourless liquid with a boiling point of 155 °C. TEC is used 
in the pharmaceutical industry as plasticizer for polymeric coating of capsules, tablets, beads 
and granules. It is GRAS listed and included in the FDA inactive ingredients guide. 
 
2.1.3. Dibutyl sebacate 
DBS is a dibutyl ester of sebacic acid. It is present as an oily, water-insoluble 
colourless liquid with a boiling point of 344-349 °C. DBS is used in oral pharmaceutical 
formulations as plasticizer for film coatings and in controlled-release tablets. It is included in 
the FDA inactive ingredients guide. 
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2.2. Polymer selection 
For the selection procedure several thermoplastic polymers were hot-melt extruded 
and evaluated for processability, macroscopic properties (surface smoothness, die swell) and 
in vitro drug release. Polymers were mixed with different amounts of drug (2.5-30% HCT; 
10-50% MPT) and hot-melt extruded using a Prism Eurolab 16 co-rotating, fully intermeshing 
twin screw extruder (ThermoFisher Scientific, Germany). The extrusion temperature varied 
according to the polymer, but all five heating segments of the extruder were set at the same 
temperature. The appropriate extrusion temperature was defined as the lowest temperature at 
which the extruder torque was below 80% motor load. A strand die with a diameter of 3 mm 
was mounted at the end of the extruder. The machine was equipped with a gravimetric 
Brabender powder feeder (Duisburg, Germany). The screw speed and feed rate were kept 
constant at 60 rpm and 250 g/h.   
 
2.3. Production of co-extrudates 
Polymer and drug were premixed in a tumbling mixer (Turbula® T2A, W.A. 
Bachofen, Basel, Switzerland) for 30 min. Co-extrusion was performed using two Prism 
Eurolab 16 co-rotating, fully intermeshing twin screw extruders (ThermoFisher Scientific, 
Germany) having a length-to-diameter ratio of 25/1. The two pairs of co-rotating screws each 
consisted of three mixing sections and a densification zone (the geometry of the screws is 
illustrated in Fig. 1). 
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Figure 1. Configuration of the intermeshing co-rotating screws. Standard screw configuration 
with three kneading blocks: transport zone (a), mixing zone (b) and densification zone (c). 
 
 A multimanifold co-extrusion die (Guill, West Warwick, USA) was connected to both 
extruders (Fig. 2). In the die, the two melts were combined to form two concentric layers, a 
core and a coat. All five heating segments of both extruders as well as the co-extrusion die 
were heated to 70 °C. Both premixes were fed into the corresponding extruders by two 
Brabender Flexwall® (loss-in-weight) powder feeders (Duisburg, Germany) at a feed rate of 
150 g/h for the coat and 250 g/h for the core material. A screw speed of 60 rpm was used in 
both extruders. The die dimensions were 3 mm core diameter and 0.5 mm coat thickness, 
resulting in a total diameter of 4 mm. After cooling down to room temperature, the cylindrical 
co-extrudates were manually cut into mini-matrices of 2 mm length. 
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Figure 2. Co-extrusion die with cylindrical core and annular coat (reprinted with permission 
of Thermo Fisher Scientific®). 
 
2.4. In vitro drug release 
Dissolution studies were performed using USP apparatus 1 (baskets). The equipment 
consisted of a VK 7010 dissolution system combined with a VK 8000 automatic sampling 
station (VanKel Industries, NJ, USA). The vessels were filled with 900 ml dissolution 
medium. The mini-matrices (six tablets of 2 mm length) were exposed to a 0.1 M solution of 
hydrochloric acid (pH=1) for 1 hour to mimic the pH of the stomach and were then 
transferred to 900 ml of demineralized water (pH=±7) for the next 23 hours to mimic the pH 
of the intestine. Sink conditions were maintained during the experiments. The bath 
temperature was kept constant at 37±0.5 °C. The rotational speed of the baskets was set to 
100 rpm. Samples (5 ml) were withdrawn at 5, 10, 15, 20, 30, 45 and 60 minutes for HCT, 
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and at 0.5, 1, 2, 4, 6, 8, 12, 16, 20, 24 hours for MPT. They were spectrophotometrically 
assessed for metoprolol tartrate and hydrochlorothiazide concentration at a wavelength of 222 
nm and 272 nm, respectively, using a Perkin-Elmer Lambda 12 UV-VIS double beam 
spectrophotometer (Zaventem, Belgium). Since the drugs showed interference at their 
respective wavelengths the release of the MPT was determined using a placebo coat and vice 
versa. 
 
2.5. Solid state characterization  
2.5.1. Differential scanning calorimetry 
 
Differential scanning calorimetry was used to study the crystallinity of the drug in the 
matrix. The thermal behavior of the individual components, physical mixtures and extrudates 
was evaluated using a Q2000 DSC (TA Instruments, Leatherhead, UK). The system was 
equipped with a refrigerated cooling system. Samples (5-10 mg) were accurately weighed and 
hermetically sealed in aluminum pans. They were cooled to -50 °C followed by heating to 150 
°C at a linear heating rate of 10 °C/min. 
 
2.5.2. Raman analysis 
Raman spectroscopy was applied to detect changes in solid-state properties of the 
model drugs. Raman spectra of drug, polymer, physical mixtures and extrudates were 
collected with a Raman RXn1 spectrometer (Kaiser Optical Systems, Ann Arbor, USA) 
equipped with an air-cooled CCD detector. The laser wavelength was the 785 nm line from a 
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785 nm Invictus NIR diode laser. The spectra were recorded at a resolution of 4cm-1 and an 
exposure time of 10 s, using a laser power of 400 mW. Data collection and data transfer were 
automated using the HoloGRAMSTM data collection software, the HoloREACTTM reaction 
analysis and profiling software, the Matlab software (version 7.1, The MathWorks Inc., 
Natick, MA) and SIMCA-P+ (version 12.0.1.0, Umetrics, Umeå, Sweden) was used for data 
analysis . The analyzed spectral region was 0 – 1800 cm-1, since this region contained all 
useful drug and polymer information. 
 
2.5.3. X-ray diffraction 
X-ray diffraction was performed to investigate the crystallinity of the drug in the mini-
matrices. X-ray patterns of drug, polymer, physical mixtures, coat and core material of the co-
extrudates were obtained using a D5000 Cu Kα Diffractor (λ = 0.154 nm) (Siemens, 
Karlsruhe, Germany). The angular range (2θ) varied from 10 to 60° (step width = 0.02°, 
counting time = 1 s/step). 
 
2.6. SEM 
Scanning electron microscopy was used to study the interface between both layers and 
to compare the surface of the mini-matrices before and after administration to dogs. Tablets 
were coated with platinum by means of a sputter coater (Auto Fine Coater, JFC-1300, Jeol, 
Tokyo, Japan). Photomicrographs were taken with a scanning electron microscope (Jeol JSM 
5600 LV, Jeol, Tokyo, Japan).  
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2.7. Adhesion 
The adhesion between core and coat was measured using a tensile tester (LF Plus, 
Lloyd Instruments, West Sussex, UK). The capacity of the load cell was 100 N. The 
experimental setup is shown in Fig. 3. The co-extrudates were cut into slices of 1 mm height 
prior to testing. The slices were placed on a holding device with a central opening of 3.3 mm. 
They were positioned in such a way that only the coat was supported by the device, while the 
core was placed over the central opening. Using a probe (diameter: 2 mm, preload: 1 N, 
extension rate: 100 mm/min), which applied a downward force on the core, the maximum 
force needed to separate the core from the coat was measured. The test was done in 20-fold.  
 
 
Figure 3. Experimental setup of the adhesion test: positioning the probe (above core) (A), 
applying a load (B), separation of core and coat (C). 
 
2.8. In vivo study 
2.8.1. Subjects and study design 
A group of six male mixed-breed dogs (weight 23.5–39.0 kg) was used in this study. 
An oral dose of 200 mg metoprolol tartrate and 25 mg hydrochlorothiazide was administered 
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to the dogs, either as experimental co-extruded mini-matrices or as reference formulation 
(Zok-Zid®, Pfizer, Brussels, Belgium). The core of the co-extrudate was formulated with 45% 
MPT, 54% polycaprolactone and 1% colloidal silicium dioxide, while the coat contained 10% 
HCT, 45% PEO and 45% PEG. 
The mini-matrices of the experimental formulation were filled in hard-gelatin 
capsules, whereas the reference formulation was given as a tablet. The formulations were 
administered in randomized order with a wash-out period of at least 1 week between sessions. 
On the experimental day the dogs were fasted for 12 h prior to the study period, although 
water was available. Before administration of a formulation, a blank blood sample was taken. 
The formulations were orally administered with 20 ml water. The blood samples were 
collected in dry heparinized tubes at fixed time points: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 
10 and 12 h after intake of the formulations. No food was administered to the dogs during the 
entire test period. Within 1 h after collection, blood was centrifuged for 10 min at 1500g. The 
plasma was separated and kept frozen at -20 °C until analysis.   
 
2.8.2. Metoprolol tartrate and hydrochlorothiazide assay 
Metoprolol tartrate and hydrochlorothiazide plasma concentrations were determined 
using two different HPLC methods. Since no interfering peaks of MPT and HCT were 
observed during the determination of HCT and MPT, respectively, the specificity of the 
methods was secured.  For MPT, a validated HPLC-fluorescence method was used [9]. 
Plasma samples (300 μl) were thoroughly mixed with 20 μl bisoprolol (7.5 μg/ml  bisoprolol 
in water, as internal standard) and 680 μl PBS. A solid phase extraction (SPE) procedure was 
used to extract metoprolol tartrate. The Oasis® HLB extraction cartridges (1 cc 30 mg) 
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(Waters, Etten-Leur, the Netherlands) were first conditioned by rinsing consecutively with 
methanol (1 ml), water (1 ml) and phosphate-buffered saline (PBS) (1 ml). Then, the prepared 
plasma samples were loaded on the columns and extracted using a 10-port vacuum manifold. 
In a next step, the columns were washed with water (1 ml) and the analytes were then eluted 
with methanol (1 ml). The eluates were evaporated to dryness under N2. After reconstitution 
in 150 μl water, 20 μl was injected on the column. The metoprolol tartrate plasma 
concentrations were determined via a calibration curve. The HPLC equipment (Merck-
Hitachi, Darmstadt, Germany) consisted of a solvent pump set at a constant flow rate of 1 
ml/min, an autosampler, a LiChrospher®  100 CN (5 μm) column (250 x 4 mm) and 
precolumn (4 x 4 mm) and a fluorescence detector set at an excitation wavelength of 275 nm 
and emission wavelength of 300 nm. The mobile phase consisted of acetonitrile/sodium 
dihydrogen orthophosphate buffer (2 M)/water (4/0.5/95.5, v/v/v). The mixture was adjusted 
to pH 3.0 with phosphoric acid. An automatic integration system (software D-7000 Multi-
Manager) was used to collect and process the signals.  
Hydrochlorothiazide was determined using a validated HPLC-UV method [10]. The 
drug was extracted from the plasma samples by means of liquid-liquid extraction. Plasma 
samples (500 μl) were thoroughly mixed with 100 μl of internal standard solution (1.25 μg/ml 
hydroflumethiazide in water). After the addition of methyl tert.-butylether (5 ml), the samples 
were vortexed (2 min) and centrifugated (5 min at 1500g). 4.5 ml of the organic phase was 
removed into a new test tube and evaporated to dryness under N2. After reconstitution of the 
residue in 200 μl of distilled water, 3 ml toluene was added. The mixture was further vortexed 
(2 min) and after 10 min of centrifugation (at 1500g), the toluene layer was removed. Once 
again 3 ml toluene was added and the extraction procedure was repeated. After removing the 
organic phase, the mixture was dried under a N2-stream at 40 °C. After reconstitution in 200 
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μl of mobile phase, 100 μl of this solution was injected into the HPLC system. The HPLC 
equipment (Merck-Hitachi, Darmstadt, Germany) consisted of a solvent pump (set at a 
constant flow rate of 0.8 ml/min), an automatic injection system, a reversed-phase C-18 
column (LiChrospher®  100 RP-18 (5 μm)) (250 x 4 mm) and precolumn (4 x 4 mm) (both 
conditioned at 40 °C) and a variable wavelength UV/VIS detector set to 272 nm. The mobile 
phase was composed of phosphate buffer pH 7/tetrahydrofurane/acetonitrile (85/10/5; v/v/v). 
An automatic integration system (software D-7000 Multi-Manager) was used for integration 
of the chromatographic peaks. 
  
2.8.3. Data analysis 
The peak plasma concentration (Cmax), the extent of absorption (AUC0-12h) and the 
time to reach Cmax (Tmax) were calculated. The relative bioavailability (Frel, expressed in %) 
was calculated as the ratio of AUC0-12h between a test formulation and the reference 
formulation. Data were statistically analysed using SPSS 17 (SPSS, Chicago, USA). To 
compare the effects of the different treatments, a paired samples t-test was performed with a 
significance level of α = 0.05.   
 
3. Results and discussion 
A successful co-extrusion process requires that both polymer melts can be processed at 
similar temperatures because they need to flow through the co-extrusion die under the same 
temperature conditions. Pure polymers and polymer-drug mixtures (in different ratios) were 
hot-melt extruded and evaluated for processability and macroscopic properties (surface 
smoothness, die swell). The appropriate extrusion temperature range for each of the polymers 
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was established in order to investigate which polymers were combinable in terms of extrusion 
temperature. Several thermoplastic polymers were assessed for their utility in co-extrusion as 
immediate release coat (Soluplus®, Eudragit® E PO, Polyox® WSR N10 (PEO), Kollidon® 
VA) and sustained release core (CAPA® 6506, Eudragit® RS PO, Ethocel® std 10, Kollidon® 
SR). By adjusting the extrusion parameters all selected polymers were processable via hot-
melt extrusion and yielded smooth extrudates, except for Kollidon® VA and SR. Extrusion 
around 160 and 140 °C of Kollidon® VA and SR, respectively, yielded extrudates with an 
irregular shape. Pure Soluplus® was extrudable in a temperature range between 140 and 180 
°C, while the addition of 10% PLUR lowered the extrusion torque, which made it possible to 
lower the extrusion temperature to 110 °C. Extrudates with a drug load up to 5% were 
transparent, while the ones containing 10% HCT were slightly opaque. For the processing of 
pure Eudragit® E PO a temperature of at least 130 °C was required, but the addition of 5 and 
10% of triethyl citrate lowered the extrusion temperature to 120 and 110 °C, respectively. 
Extrudates composed of only the polymer and triethyl citrate were transparent, whereas the 
ones containing HCT were all white. The minimal extrusion temperature for PEO was 75 °C, 
but extrusion at higher temperatures (130 °C) was also possible. At 75 °C, all PEO/HCT 
extrudates were brigthly yellow and transparent. Nevertheless, they became opaque after 
cooling down to room temperature due to the recrystallization of the PEO. The addition of 
50% of PEG 4000 to PEO resulted in lower torque values. Polycaprolactone was already 
processable at a temperature of 70 °C without the use of any plasticizer, whereas the extrusion 
of Eudragit® RS PO without plasticizer was impossible. The temperature required to extrude 
pure Eudragit® RS PO approached the degradation temperature of the polymer (140-150 °C). 
Hence the addition of 10% triethyl citrate was required to reduce the extrusion temperature to 
120 °C. Polycaprolactone yielded white extrudates at all tested MPT concentrations since the 
extrusion temperature was far below the melting point of MPT, whereas using Eudragit® RS 
Co-extrusion as manufacturing technique for fixed-dose 
combination mini-matrices CHAPTER 2 
 
66 
 
PO as a carrier the extrudates were all transparent. Extrusion of ethylcellulose also required a 
plasticizer. The addition of 20% dibutyl sebacate allowed extrusion at 120 °C. The obtained 
extrudates were not transparent. These above mentioned data showed that some polymers 
could be extruded at relatively low temperatures (polycaprolactone, PEO), while others 
required higher temperatures (Soluplus®, Eudragit® E & RS PO, ethylcellulose, PEO).  
The polymers that yielded good quality extrudates were further tested for in vitro drug 
release. The dissolution profiles are shown in Fig. 4. The release of HCT from Eudragit® E 
PO was already complete in 30 minutes, whereas it took 1 hour for HCT to be released from 
PEO. In contact with the acidic dissolution medium, Eudragit® E PO became ionized and 
dissolved in the medium hereby releasing the drug. The solubility of PEO was pH 
independent and it took more time for this coat to dissolve. Nevertheless, the addition of 50% 
polyethylene glycol 4000 (PEG) to PEO resulted in a considerable increase in release rate 
(100% release in <30 min). HCT release from Soluplus® was incomplete after 1 h. Very low 
drug concentrations (2,5% HCT) were released relatively fast from Soluplus®, but with an 
increasing drug load (5% or more) the release rate dropped considerably (only 20% release 
after 1 h). Whereas the extrudates with 2,5% HCT had completely dissolved after 1 h, the 
ones with 5% HCT were swollen. Polycaprolactone and ethylcellulose provided sustained 
release of MPT. The extent of the release sustaining effect from these matrices depended on 
drug load: a lower drug concentration resulted in a slower release rate. Eudragit® RS showed 
a limited release retarding effect and it was impossible to sustain MPT release over 24 h with 
this polymer.  
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Figure 4. Influence of drug load on the release of HCT (A-C) and MPT (D-F) from different 
polymers after extrusion. Mean dissolution profiles (±S.D.) of formulations composed of A: 
Soluplus® and () 2.5%, () 5%, (▲) 10% HCT; B: Eudragit® E PO and () 10%, () 20%, 
(▲) 30% HCT; C: Polyox®, 10% HCT and () 0%, () 50% PEG 4000; D: Polycaprolactone 
and () 20%, () 30%, (▲) 35%, () 40%, () 50% MPT; E: Eudragit® RS PO and () 
10%, () 20%, (▲) 30% MPT; F: Ethylcellulose and () 20%, () 30% MPT. 
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Taking into account the processability and the in vitro drug release data four polymers 
were selected: Eudragit® E PO and PEO (with 50% PEG) for immediate release, and 
polycaprolactone and ethylcellulose for sustained release. Based on the extrusion temperature 
data, two polymer combinations were considered for co-extrusion: ethylcellulose core with 
Eudragit® E PO coat (both extrudable around 120 °C) and polycaprolactone core with PEO 
coat (both extrudable around 70 °C). The polycaprolactone/PEO combination was finally 
selected for co-extrusion trials as these polymers could be processed at a low extrusion 
temperature (70 °C). 
All co-extruded formulations consisted of a polycaprolactone-core and a PEO/PEG-
coat but contained different drug concentrations of drug (10, 20, 30, 35, 40, 45, 50% MPT in 
the core and 10, 20, 30% HCT in the coat). Due to the poor flow properties of the 
polycaprolactone-MPT mixtures in the feeder 1% (w/w) colloidal silicium dioxide was added 
to the formulation. Polycaprolactone, a biodegradable polyester, possesses excellent 
thermoplastic properties and has a melting point of 58-60 °C. Formulations composed of 
unplasticized polycaprolactone were hot-melt extruded at temperatures between 70 and 80 °C. 
Below 70 °C, the melt viscosity was too high resulting in a high torque and an inadequate 
flow from the extruder, while above 80 °C thinner extrudates with a rough surface were 
obtained.  
PEO (100,000 g/mol), a semi-crystalline non-ionic hydrophilic polymer which has 
previously been studied for hot-melt applications [11], has a melting point of 65-70 °C, 
whereas the lower molecular weight PEG (4,000 g/mol) exhibits a melting point of 50-58 °C. 
The ratio PEO/PEG in all coating formulations was 1/1. Preliminary studies indicated that at 
higher PEG content, the drug release rate increased while the extrudates tended to be more 
brittle. The addition of 50% (w/w) PEG resulted in a 100% drug release in less than 60 min 
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and good co-extrudate quality. The different formulations were easily processed at an 
extrusion temperature of 70 °C. The layer thickness was uniform, as confirmed with a 
marking gauge. No surface defects were detected and the extrudates having a smooth surface 
were cut into high quality mini-tablets.  
After extrusion, the core and coat of the co-extrudates were physico-chemically 
characterized. Since pure metoprolol tartrate is crystalline, its Raman spectrum contained 
narrow, well defined peaks. No significant peak broadening was observed for the core 
compared to the pure drug, indicating crystalline MPT in the core of the co-extrudates (Fig. 
5). The X-ray diffractogram of MPT showed distinct crystalline peaks at 2θ of 19.4 and 23.1 
and a series of smaller peaks at 10.6, 15.8, 20.4 and 24.0 (Fig. 6). Those peaks were also 
present in the diffractogram of the core, confirming the crystalline state of MPT. The DSC 
thermogram of MPT (Fig. 7) showed a melting peak at 124.25 °C, the enthalpy of fusion 
indicated that the entire drug fraction remained crystalline. According to literature [12], the 
amorphous content of polycaprolactone remains relatively unchanged after hot-melt extrusion 
regardless of cooling rate. A higher amorphous content typically results in higher drug 
solubility, as drug molecules are soluble in the amorphous regions of the polymer. In this 
case, the extrusion process did not cause a considerable decrease in crystalline fraction of 
polycaprolactone as indicated by the enthalpy of fusion (Fig. 7).  
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Figure 5. Raman spectra of MPT, polycaprolactone (CAPA), core of co-extruded tablet 
composed of 40/1/59% MPT/CSD/polycaprolactone, physical mixture (PM). 
 
 
Figure 6. X-ray diffraction pattern of (A) MPT, (B) polycaprolactone, (C) colloidal silicium 
dioxide, (D) physical mixture and (E) extrudate composed of 40/1/59% 
MPT/CSD/polycaprolactone.  
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Figure 7. Differential scanning calorimetry profiles. From the top to the bottom: metoprolol 
tartrate, polycaprolactone, colloidal silicium dioxide, physical mixture and core of co-
extruded tablet composed of 40/1/59% MPT/CSD/polycaprolactone. 
 
The diffraction pattern of pure HCT revealed crystalline peaks which were also 
detected in the physical mixture (Fig. 8). The absence of these peaks in the diffractogram of 
the coat revealed that there were no drug crystals left in the coat of the co-extrudate. Since the 
melting point of HCT (274 °C) was never reached during the extrusion process, this indicated 
that HCT had dissolved in the PEO/PEG-matrix. These results were confirmed with Raman 
spectroscopy. Compared to the Raman spectrum of pure HCT, the HCT peaks in the extrudate 
were broader and flatter, demonstrating loss of crystallinity (Fig. 9). Other investigators 
already described the solubilization of drugs in PEO during extrusion [11, 13], which could be 
useful for solubility enhancement. After 12 months of storage at ambient conditions (25 °C), 
the Raman spectra, X-ray diffractrograms and DSC thermograms remained unchanged. 
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Figure 8. X-ray diffraction pattern of (A) HCT, (B) PEO/PEG (1/1), (C) physical mixture and 
(D) extrudate composed of 10/45/45% HCT/PEO/PEG. 
 
 
Figure 9. Raman spectra of HCT, PEO/PEG (1/1), physical mixture (PM) and extrudate 
composed of 10/45/45% HCT/PEO/PEG. 
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The SEM picture (Fig. 10A) clearly showed the two layers in the mini-tablets and 
indicated that core and coat were well attached to each other. The adhesion force between 
both layers was measured. For the formulation that contained 45% (w/w) MPT in the core and 
10% (w/w) HCT in the coat the average force needed to separate core from coat was 10.5 ± 
3.1 N. 
 
 
Figure 10. SEM images of co-extrudate with a core composed of 45/55% 
MPT/polycaprolactone and a coat composed of 10/45/45% HCT/PEO/PEG. (A) Immediately 
after production (magnification 60x), (B) After faecal recovery (70x). 
 
Immediate and sustained drug release was observed from the coat and core 
respectively (Fig. 11 & 12). Fig. 11 shows the influence of drug load on the release of HCT 
from the coat. Formulations with drug loads up to 20% (w/w) provided a release of 100% in 
30 min. Although HCT was completely dissolved in formulations with a drug load of 30% 
(w/w), a slower drug release was observed (100% released in 1 h) due to the slower 
dissolution of the coat compared to formulations containing a higher PEG/PEO fraction. The 
dissolution rate of MPT from the core is controlled by the drug/carrier ratio (Fig. 12): the 
release rate increased at higher MPT content in the core of the formulation. At higher MPT 
Coat/core interface 
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concentration (45 and 50%) full drug release was observed after 24 h. There was no 
significant effect of the extrusion temperature on the release rate from the core when 
increasing the temperature from 70 to 80 °C. However, an extrusion temperature of 90 °C 
resulted in a significant faster release, which (after visual inspection) could be attributed to the 
smaller diameter (and as a consequence higher surface area) of these samples in comparison 
to the formulations extruded below 90 °C. The drug release characteristics of the coat were 
not influenced by the extrusion temperature. Based on the dissolution results, a formulation 
containing 45% MPT in the core and 10% HCT in the coat was selected for in vivo testing. 
The MPT/HCT ratio in this system was similar to the reference formulation (Zok-Zid®). After 
12 months storage at ambient conditions the release profile of the experimental formulation 
remained unaltered. Considering also the solid state, this indicated that the formulation was 
stable for at least 12 months at ambient conditions. 
 
 
Figure 11. Influence of drug load on HCT release from the coat of co-extruded mini-matrices. 
The coat was composed of PEO/PEG (1/1) and variable HCT concentrations: () 10%, () 
20%, (∆) 30%, (---) reference formulation (Zok-Zid®). 
0
20
40
60
80
100
0 20 40 60
C
um
ul
at
iv
e 
dr
ug
 re
le
as
e 
(%
) 
Time (min) 
Co-extrusion as manufacturing technique for fixed-dose 
combination mini-matrices CHAPTER 2 
 
75 
 
 
 
Figure 12. Influence of drug load on MPT release from the core of co-extruded mini-
matrices. The core was composed of polycaprolactone and variable MPT concentrations: (∆) 
30%, () 40%, () 45%, () 50%, (---) reference formulation (Zok-Zid®). 
 
Fig. 13 shows the mean plasma concentration-time profiles after oral administration of 
200 mg MPT and 25 mg HCT as experimental mini-matrices and Zok-Zid® (2 tablets). 
Although Zok-Zid® is administered as a tablet, in contact with fluids it immediately 
disintegrated into pellets, creating a multiparticulate system: hydroxypropyl cellulose-based 
pellets containing HCT and pellets composed of ethylcellulose and MPT. According to the 
dissolution data, both test and reference formulation provided immediate release (less than 30 
min) of HCT and sustained MPT release over 24 h. However, the in vitro MPT release from 
the reference formulation was considerably slower, which was also reflected in the in vivo 
behaviour. The pharmacokinetic parameters of MPT and HCT are reported in Table 2. 
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Figure 13. Mean MPT () and HCT (▲) plasma concentration-time profiles (± SD, n = 6) 
after oral administration of 200 mg metoprolol tartrate and 25 mg hydrochlorothiazide to 
dogs: Zok-Zid® (2 tablets) (dotted line), experimental co-extruded mini-matrices with a core 
consisting of 45% (w/w) MPT and a coat consisting of 10% (w/w) HCT (full line).  
 
Table 2. Mean pharmacokinetic parameters (±S.D.) of MPT and HCT after oral 
administration of 200 mg metoprolol tartrate and 25 mg hydrochlorothiazide to dogs (n=6), as 
experimental co-extruded mini-matrices (with a core consisting of 45% (w/w) MPT and a coat 
consisting of 10% (w/w) HCT) or as reference formulation (Zok-Zid®). 
MPT HCT 
 
Cmax (ng/ml) Tmax (h) AUC (ng.h/ml) Cmax (ng/ml) Tmax (h) AUC (ng.h/ml) 
Exp 73.6 ± 46.9 2.8 ± 0.7 345.2 ± 257.9 371.6 ± 126.0 1.6 ± 0.5 1353.8 ± 320.3 
Ref 23.5 ± 19.7 4.2 ± 1.2 117.1 ± 95.6 459.9 ± 227.0 2.5 ± 1.1 1479.3 ± 346.5 
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 Fig. 14 represents the AUC values of each dog separately after administration of the 
experimental and the reference formulation. The bioavailability data of HCT (Cmax, Tmax & 
AUC) of both formulations were comparable, without a statistical significant difference 
between the test and reference formulations (p > 0.05). Although there was a trend that the 
MPT bioavailability of the test formulation for each dog was higher than the reference (Fig. 
14A), the difference was statistically not significant. Besides that, the variability in AUC 
values for MPT was higher after administration of the experimental formulation than for the 
reference formulation. While the coat of the co-extrudates dissolved during gastro-intestinal 
passage, intact cores (which still contained 6.6 ± 0.4% of the initial MPT dose) were 
recovered from the faeces of the dogs. As no swelling or erosion was observed while the pore 
size increased (Fig. 10B), release from the caprolactone core was diffusion-controlled. 
 
 
Figure 14. Comparison of AUC level of MPT (A) and HCT (B) after oral administration of 
experimental co-extruded and reference formulation to dogs. 
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4. Conclusions 
This study showed that co-extrusion seems a promising technique to produce fixed-
dose combination mini-matrices. A core/coat dosage form was developed, wherein the core 
and coat exhibited sustained and immediate release properties, using a combination of 
polycaprolactone (core) and PEO/PEG (coat). There was good adhesion between the two 
layers. The solid state characterization revealed that MPT maintained its crystalline form 
whereas HCT was molecularly dispersed in the coat of the co-extrudates. The differences in in 
vivo performance between a reference formulation and the test formulation were statistically 
not significant. 
 
Acknowledgements 
The authors wish to thank Mr. Daniël Tensy for the contribution in the in vivo study and 
BASF for the generous supply of polymers. 
  
Co-extrusion as manufacturing technique for fixed-dose 
combination mini-matrices CHAPTER 2 
 
79 
 
References 
 
[1] H. Bechgaard, G.H. Nielsen, Controlled-release multiple-units and single-unit doses - 
Literature-review, Drug Development and Industrial Pharmacy, 4 (1978) 53-67. 
[2] D. Shukla, S. Chakraborty, S. Singh, B. Mishra, Lipid-based oral multiparticulate 
formulations - advantages, technological advances and industrial applications, Expert Opinion 
on Drug Delivery, 8 (2011) 207-224. 
[3] F. Pan, M.E. Chernew, A.M. Fendrick, Impact of fixed-dose combination drugs on 
adherence to prescription medications, Journal of General Internal Medicine, 23 (2008) 611-
614. 
[4] R. Lewanczuk, S.W. Tobe, More medications, fewer pills: Combination medications for 
the treatment of hypertension, Canadian Journal of Cardiology, 23 (2007) 573-576. 
[5] M.A.S. Pires, R.A.S. dos Santos, R.D. Sinisterra, Pharmaceutical Composition of 
Hydrochlorothiazide:beta-Cyclodextrin: Preparation by Three Different Methods, Physico-
Chemical Characterization and In Vivo Diuretic Activity Evaluation, Molecules, 16 (2011) 
4482-4499. 
[6] S.C. Sweetman, Martindale : the complete drug reference, Pharmaceutical Press, London, 
2011. 
[7] Z. Vujic, N. Mulavdic, M. Smajic, J. Brboric, P. Stankovic, Simultaneous Analysis of 
Irbesartan and Hydrochlorothiazide: An Improved HPLC Method with the Aid of a 
Chemometric Protocol, Molecules, 17 (2012) 3461-3474. 
[8] T. Quinten, T. De Beer, C. Vervaet, J.P. Remon, Evaluation of injection moulding as a 
pharmaceutical technology to produce matrix tablets, European Journal of Pharmaceutics and 
Biopharmaceutics, 71 (2009) 145-154. 
Co-extrusion as manufacturing technique for fixed-dose 
combination mini-matrices CHAPTER 2 
 
80 
 
[9] J. Fang, H.A. Semple, J.X. Song, Determination of metoprolol, and its four metabolites in 
dog plasma, Journal of Chromatography B-Analytical Technologies in the Biomedical and 
Life Sciences, 809 (2004) 9-14. 
[10] C. Vervaet, J.P. Remon, Bioavailability of hydrochlorothiazide from pellets, made by 
extrusion/spheronisation, containing polyethylene glycol 400 as a dissolution enhancer, 
Pharmaceutical Research, 14 (1997) 1644-1646. 
[11] L. Li, O. AbuBaker, Z.Z.J. Shao, Characterization of poly(ethylene oxide) as a drug 
carrier in hot-melt extrusion, Drug Development and Industrial Pharmacy, 32 (2006) 991-
1002. 
[12] P. Douglas, G. Andrews, D. Jones, G. Walker, Analysis of in vitro drug dissolution from 
PCL melt extrusion, Chemical Engineering Journal, 164 (2010) 359-370. 
[13] M.M. Crowley, F. Zhang, J.J. Koleng, J.W. McGinity, Stability of polyethylene oxide in 
matrix tablets prepared by hot-melt extrusion, Biomaterials, 23 (2002) 4241-4248. 
Co-extrusion as manufacturing technique for multilayer mini-
matrices with dual drug release CHAPTER 3 
 
81 
 
 
 
 
 
 
 
CHAPTER 3 
Co-extrusion as manufacturing technique for 
multilayer mini-matrices with dual drug release 
 
 
 
 
 
 
 
Parts of this chapter are published in: L. Dierickx, J.P. Remon, C. Vervaet, Co-extrusion as 
manufacturing technique for multilayer mini-matrices with dual drug release, European 
Journal of Pharmaceutics and Biopharmaceutics, 85 (2013) 1157-1163. 
Co-extrusion as manufacturing technique for multilayer mini-
matrices with dual drug release CHAPTER 3 
 
82 
 
  
Co-extrusion as manufacturing technique for multilayer mini-
matrices with dual drug release CHAPTER 3 
 
83 
 
1. Introduction 
Extended release drug delivery systems improve the life quality of chronic and poly-
medicated patients by reducing their daily intake of dosage forms, thereby improving patient 
compliance. Prolonged release dosage forms have a greater duration of action than 
conventional dosage forms, but the onset of action is often delayed. The aim of the present 
study was to design by means of co-extrusion a solid dosage form for oral application which 
provides dual release of a single drug: a layer with immediate drug release to ensure a fast 
onset of action, in combination with a sustained release layer to sustain the activity of the drug 
over a longer period. In this study, diclofenac sodium (DS) was incorporated as model drug in 
the co-extruded formulation. DS is a non-steroidal anti-inflammatory drug (NSAID) used in 
the long-term treatment of inflammation and painful conditions of rheumatic and non-
rheumatic origin. It is sparingly soluble in water, rapidly absorbed in the gastrointestinal tract 
and exhibits a plasma half-life of about 1 to 2 h. Due to its biopharmaceutical and 
pharmacological properties, sustained release of DS is desirable. In addition, it has been 
shown that a non-enteric coated NSAID formulation has pharmacokinetic advantages (less 
variation in e.g. lag-time and time to peak plasma concentration) over an enteric coated 
formulation [1]. The aim of the present study was to design a core/coat dosage form via co-
extrusion to obtain a dual release rate of DS, the inner core providing sustained drug release 
(SR) and the outer (non-enteric) coat immediate drug release (IR).  
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2. Materials and methods 
2.1. Materials 
The following polymers were used during the polymer screening experiments: 
Kollidon® VA and SR, Soluplus® (BASF, Ludwigshafen, Germany), Eudragit® E and RS PO 
(Evonik, Darmstadt, Germany), Ethocel® std 10 (ethylcellulose, DOW Chemical Company, 
Midland, USA), SentryTM Polyox® WSR N10 (polyethylene oxide, PEO 100,000 g/mol, 
Colorcon, Dartford Kent, United Kingdom), polyethylene glycol (PEG 4000 g/mol, Fagron, 
Waregem, Belgium) and CAPA® 6506 (polycaprolactone 50,000 g/mol, Perstorp, Warrington, 
United Kingdom). Dibutylsebacate (DBS), triethyl citrate (TEC) and Pluronic® F-68 (PLUR) 
(Sigma–Aldrich, Steinheim, Germany) were used as plasticizers for Ethocel® and Soluplus®, 
respectively. Colloidal silicon dioxide (Fagron, Waregem, Belgium) was added to CAPA® to 
improve the flow properties. Diclofenac sodium (DS, Fagron, Waregem, Belgium) was 
incorporated as model drug. Its relevant physico-chemical properties are listed in Table 1. All 
other chemicals were of analytical grade.  
 
Table 1. Physico-chemical properties of diclofenac sodium.
Properties Structural formula 
Melting point  284 °C 
 
Degradation temperature 270-390 °C [2] 
Solubility in water sparingly soluble [3] 
pKa 4 
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2.2. Polymer selection 
For the selection procedure several thermoplastic polymers were hot-melt extruded 
and evaluated for processability, macroscopic properties (visual inspection of surface, die 
swell quantification using marking gauge) and in vitro drug release. Polymers were mixed 
with different amounts (10-60%) of DS and hot-melt extruded using a co-rotating, fully 
intermeshing twin screw extruder (Prism Eurolab 16, ThermoFisher Scientific, Germany). 
The extrusion temperature varied according to the polymer, but all five heating segments of 
the extruder were set at the same temperature, except for the first heating zone which was set 
at 70 °C to avoid sticking of the powder in the feed section. A strand die with a diameter of 3 
mm was mounted at the end of the extruder. The machine was equipped with a gravimetric 
powder feeder (Brabender, Duisburg, Germany). The screw speed and feed rate were kept 
constant at 60 rpm and 150 g/h.   
 
2.3. Production of co-extrudates 
Polymer and drug were premixed in a tumbling mixer (Turbula® T2A, W.A. 
Bachofen, Basel, Switzerland) for 20 min. Co-extrusion was performed using two co-rotating, 
fully intermeshing twin screw extruders (Prism Eurolab 16, ThermoFisher Scientific, 
Germany) having a length-to-diameter ratio of 25/1. The two pairs of co-rotating screws each 
consisted of three mixing sections and a densification zone. A multimanifold co-extrusion die 
(Guill, West Warwick, USA) was connected to both extruders. In the die, the two melts were 
combined to form two concentric layers, a core and a coat. Table 2 shows the composition of 
the co-extruded formulations as well as the extrusion conditions used for each formulation. 
Formulation 1 (F1) was composed of an ethylcellulose-core in combination with a Soluplus®-
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coat. Formulations 2 to 12 (F2-F12) consisted of a polycaprolactone-core and a PEO/PEG-coat 
loaded with different DS concentrations. Formulations 2 to 4 (F2-F4) were used in the in vivo 
study, whereas formulations 5 to 12 (F5-F12) were used to investigate the influence of drug 
load and extrusion temperature on core/coat adhesion. All five heating segments of both 
extruders as well as the die were set at the same temperature, except for the first heating zone 
which was set at 70 °C to avoid sticking of the powder in the feed section. The premixes were 
fed into the extruders using loss-in-weight powder feeders (Brabender Flexwall®, Duisburg, 
Germany). The die dimensions varied (core diameter: 2/3 mm; coat thickness: 0.5/1 mm) 
(Fig. 1b) though the total die diameter was 4 mm. After cooling down to room temperature, 
the cylindrical co-extrudates were manually cut into mini-matrices of 2 mm length.  
 
Table 2. Composition and extrusion parameters of co-extruded formulations. 
 
DS concentration 
(%) 
Textr  
(°C) 
Feed rate  
(g/h) 
Screw speed  
(rpm) 
Die dimensions  
(mm) 
DS ratio 
core:coat 
 core coat  core coat core coat core coat  
F1 60 25 140 200 200 60 60 3 0.5 70:30 
F2 50 22.5 95 150 150 60 60 3 0.5 70:30 
F3 50 50 95 200 150 60 60 3 0.5 57:43 
F4 50 50 120 200 600 80 80 2 1 25:75 
F5 0 0 70 200 150 60 60 3 0.5 - 
F6 0 0 95 200 150 60 60 3 0.5 - 
F7 0 0 120 200 150 60 60 3 0.5 - 
F8 30 30 70 200 150 60 60 3 0.5 57:43 
F9 30 30 95 200 150 60 60 3 0.5 57:43 
F10 30 30 120 200 150 60 60 3 0.5 57:43 
F11 50 50 95 200 150 60 60 3 0.5 57:43 
F12 50 50 120 200 150 60 60 3 0.5 57:43 
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Figure 1b. Different dimensions of co-extrusion die. 
 
2.4. X-ray diffraction 
X-ray diffraction was performed to investigate the crystallinity of the drug in the mini-
matrices. X-ray patterns of drug, polymer, physical mixtures, coat and core material of the co-
extrudates were obtained using a D5000 Cu Kα Diffractor (λ = 0.154 nm) (Siemens, 
Karlsruhe, Germany). The angular range (2θ) varied from 10° to 60° (step width = 0.02°, 
counting time = 1 s/step). 
 
2.5. Differential scanning calorimetry 
Differential scanning calorimetry was used to study the crystallinity of DS in the 
formulation. The thermal behavior of the individual components, physical mixtures and 
extrudates was evaluated using a Q2000 DSC (TA Instruments, Leatherhead, UK). The 
system was equipped with a refrigerated cooling system. Samples (5-10 mg) were accurately 
weighed and hermetically sealed in aluminum pans. They were cooled to 0 °C followed by 
heating to 300 °C at a linear heating rate of 10 °C/min. 
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2.6. Adhesion 
The adhesion between core and coat was measured using a tensile tester (LF Plus, 
Lloyd Instruments, West Sussex, UK). The capacity of the load cell was 100 N. The co-
extrudates were cut into slices of 1 mm height prior to testing. The slices were placed on a 
holding device with a central opening of 3.3 mm. They were positioned in such a way that 
only the coat was supported by the device, while the core was placed over the central opening. 
Using a probe (diameter: 2 mm, preload: 1 N, extension rate: 100 mm/min), which applied a 
downward force on the core, the maximum force needed to separate the core from the coat 
was measured. The test was done in 20-fold.  
 
2.7. SEM 
Scanning electron microscopy was used to study the interface between both layers. 
Co-extrudates were sliced in order to visualize the cross section. Besides coat and core were 
separated using a tensile tester (see section 2.6) and the interfacial contact surfaces of core 
and coat were investigated. Samples were coated with platinum by means of a sputter coater 
(Auto Fine Coater, JFC-1300, Jeol, Tokyo, Japan). Photomicrographs were taken with a 
scanning electron microscope (Jeol JSM 5600 LV, Jeol, Tokyo, Japan). 
 
2.8. In vitro drug release 
Dissolution studies were performed using USP apparatus 1 (baskets). The equipment 
consisted of a VK 7010 dissolution system combined with a VK 8000 automatic sampling 
station (VanKel Industries, NJ, USA). The vessels were filled with 900 ml dissolution 
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medium. Distilled water (900 ml) was used as dissolution medium. Sink conditions were 
maintained during the experiments. The bath temperature was kept constant at 37 ± 0.5 °C. 
The rotational speed of the baskets was set to 100 rpm. Samples (5 ml) were withdrawn at 5, 
10, 15, 20, 30, 45 and 60 min for the coat and at 0.5, 1, 2, 4, 6, 8, 12, 16, 20, 24 h for the core. 
They were analyzed spectrophotometrically for DS at 276 nm by means of a Perkin-Elmer 
Lambda 12 UV-VIS double beam spectrophotometer (Zaventem, Belgium).   
 
2.9. In vivo study 
A group of six male mixed-breed dogs (weight 23.5–39.0 kg) was used in this study. 
An oral dose of 100 mg diclofenac sodium was administered to the dogs, either as 
experimental co-extruded mini-matrices or as reference formulation. Three experimental 
formulations (F2, F3 and F4, which differed in DS content in the core and coat, Table 2) were 
selected for the in vivo study. Motifene® (Daiichi-Sankyo) was chosen as a multiparticulate 
reference formulation. 
The mini-matrices of the experimental formulations and the Motifene® pellets were 
filled in hard-gelatin capsules. The formulations were administered in randomized order with 
a wash-out period of at least 1 week between sessions. On the experimental day the dogs were 
fasted for 12 h prior to the study period, although water was available. Before administration 
of a formulation, a blank blood sample was taken. The formulations were orally administered 
with 20 ml water. The blood samples were collected in dry heparinized tubes at fixed time 
points: 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h after intake of the formulations. No food 
was administered to the dogs during the entire test period. Within 1 h after collection, blood 
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was centrifuged for 10 min at 1500g. The plasma was separated and kept frozen at -20 °C 
until analysis.   
The determination of diclofenac plasma concentrations was based on a validated 
HPLC-fluorescence method [4]. Plasma samples (500 μl) were thoroughly mixed with 50 μl 
flurbiprofen (50 μg/ml  flurbiprofen in methanol, as internal standard) and 450 μl phosphoric 
acid (1 M). A solid phase extraction (SPE) procedure was used to extract diclofenac. The 
Oasis® HLB extraction cartridges (1 cc 30 mg) (Waters, Etten-Leur, the Netherlands) were 
first conditioned by rinsing consecutively with methanol (1 ml) and water (1 ml). Then, the 
prepared plasma samples were loaded onto the extraction cartridges. A wash step was 
performed using 1 ml of 5% aqueous methanol and the samples were  eluted using 1 ml of 
methanol. The eluates were evaporated to dryness under N2. The residue was reconstituted in 
150 μl of mobile phase and 100 μl was injected on the column. The diclofenac plasma 
concentrations were determined via a calibration curve. The HPLC equipment (Merck-
Hitachi, Darmstadt, Germany) consisted of a solvent pump (set at a constant flow rate of 1 
ml/min), an automatic injection system, a reversed-phase C-18 column (LiChrospher® 100 
RP-18 (5 μm)) (250 x 4 mm) and precolumn (4 x 4 mm) and a UV detector set to 280 nm. 
The mobile phase was composed of methanol/water (adjusted to pH 3.3 with H3PO4) (63/37; 
v/v). An automatic integration system (software D-7000 Multi-Manager) was used for 
integration of the chromatographic peaks. 
The peak plasma concentrations (Cmax1, Cmax2), the extent of absorption (AUC0-12h) and 
the time to reach Cmax (Tmax1, Tmax2) were calculated. Data were statistically analyzed using 
SPSS 17 (SPSS, Chicago, USA). The effect of the formulation on the bioavailability was 
assessed by repeated-measures ANOVA (univariate analysis). To compare the effects of the 
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different treatments, a multiple comparison among pairs of means was performed using a 
Bonferroni post-hoc test with a significance level of α = 0.05.   
 
3. Results and discussion 
3.1. Polymer selection  
As co-extruded dosage forms offer a lot of opportunities for oral applications via the 
proper selection of the polymers used in the different layers, the aim of this work was to 
design a formulation providing dual release of diclofenac sodium. To select the polymers 
incorporated in the immediate and sustained release layer, the same strategy was used as 
during the development of FDC mini-matrices via co-extrusion [5], i.e. for each layer the 
polymers were selected by performing conventional hot-melt extrusion experiments, prior to 
initiating co-extrusion trials. Several thermoplastic polymers that have been successfully used 
in hot-melt extrusion were assessed for their application in co-extrusion as immediate release 
coat (Soluplus®, Eudragit® E PO, Polyox® WSR N10 (PEO), Kollidon® VA) and sustained 
release core (CAPA® 6506, Eudragit® RS PO, Ethocel® std 10, Kollidon® SR). These 
polymers were mixed in different ratios with DS, hot-melt extruded and evaluated for 
processability and macroscopic properties (surface smoothness, die swell).  
All polymers were processable via hot-melt extrusion and smooth extrudates were 
obtained, except for the Kollidon® polymers which yielded extrudates with an irregular 
surface. According to [5], extrusion of pure Soluplus® required high temperatures (140-180 
°C), while the addition of PLUR improved the ease of processing of this polymer. Mixtures of 
Soluplus®/PLUR (ratio: 9/1) containing up to 30% DS were extruded at 130 °C with an 
acceptable torque (50-70% motor load). Unplasticized mixtures of Eudragit® E PO and up to 
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20% DS could be extruded at 140 °C, but higher drug concentrations resulted in too high 
torque values (>80% motor load). The addition of PEG 4000 to PEO/DS mixtures improved 
processing by lowering the extruder torque and die pressure. The advantage of the addition of 
PEG to a PEO-containing formulation was already shown in a previous study [5], the 
incorporation of PEG 4000 lowered the torque during extrusion, a PEG/PEO ratio of 1/1 
yielding the best results. These PEO/PEG/DS mixtures were extruded at 70 °C, resulting in 
low torque values (<50% motor load). Polycaprolactone (loaded with maximum 50% DS) 
was processable at a temperature of 70 °C without the addition of a plasticizer. However, the 
addition of 1% colloidal silicon dioxide was required to improve the flow properties in the 
feeder. Mixtures of Eudragit® RS PO/triethyl citrate (9/1) with up to 30% DS were extruded 
at 130 °C. Dibutyl sebacate (20% (w/p)) was used as a plasticizer for ethylcellulose. 
Plasticized mixtures containing up to 60% DS were extruded at 140 °C. No significant die 
swell was observed for the tested polymers. 
The polymers that yielded good quality extrudates were further tested for in vitro drug 
release. The dissolution profiles are shown in Fig. 2. Two polymers (PEO/PEG (1/1) and 
Soluplus®) provided immediate drug release, the DS release from these matrices was 
complete in 30 min. Varying the drug load from 10 to 30% DS in these polymers, did not 
affect the release rate. DS release from extrudates formulated with Eudragit® E PO was 
incomplete after 1 h dissolution testing in water as well as in 0.1 N HCl. Since Eudragit® E 
PO is only soluble in acidic media, the matrix remained intact in water which prevented 
immediate drug release. In contrast, in an acidic medium the polymer dissolved, but due to 
low solubility of DS at low pH the released drug crystals did not dissolve. Hence, Eudragit® E 
PO was not a proper carrier for the coat of co-extrudates containing DS. Two polymers 
provided sustained release of DS: polycaprolactone and ethylcellulose. The dissolution 
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profiles showed that increasing the DS concentration enhanced the release rate. A drug load of 
60% DS in ethylcellulose and 50% DS in polycaprolactone resulted in ±100% release after 24 
h. It was not possible to sustain the release of DS using Eudragit® RS as - after an initial burst 
release - the release leveled off, resulting in an incomplete DS release after 24 h. This is 
probably due to the drug load in these formulations which is below the percolation threshold, 
whereby drug particles entrapped in the water-insoluble matrix are not accessible for the 
dissolution liquid.  
  
 
Figure 2. Influence of drug load on the release of DS from different polymers after extrusion. 
Mean dissolution profiles (±S.D.) of formulations composed of (A) Soluplus®/PLUR (9/1), 
(B) Eudragit® E PO, (C) PEO/PEG (1/1), (D) Polycaprolactone, (E) Eudragit® RS PO/TEC 
(9/1), (F) Ethylcellulose/DBS (8/2) and () 10%, () 20%, (▲) 25% DS, () 30% DS, (●) 
40% DS, (□) 50% DS, (○) 60% DS. 
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During the polymer screening four polymers were identified as useful for co-extrusion 
in terms of processability and in vitro drug release: Soluplus® and PEO (with 50% PEG) 
provided immediate release, while DS release from polycaprolactone and ethylcellulose was 
sustained over a 24 h period. Taking into account their respective extrusion temperatures, two 
polymer combinations were selected for co-extrusion trials: ethylcellulose (core) combined 
with Soluplus® (coat), and polycaprolactone (core) with polyethylene oxide (coat). The 
polycaprolactone/PEO combination could be processed at a lower extrusion temperature (70 
°C), vs. 140 °C for ethylcellulose/Soluplus®. Previous work by the authors [5] already 
demonstrated the success of the combination of the polycaprolactone/PEO combination as 
sustained release core and immediate release coat in co-extrusion.   
 
3.2. Production and characterization of co-extrudates 
All formulations complied for content uniformity. The thickness of the coat and core 
was uniform, as confirmed with marking gauge. Co-extruded formulations with a core 
composed of ethylcellulose/DBS (4/1) and a coat consisting of Soluplus®/PLUR (9/1) were 
processed at a temperature of 140 °C. The maximum drug load (MDL) in ethylcellulose at 
this temperature was approximately 60% DS, resulting in a torque value of 65% motor load 
and a die pressure of 19 bar. The MDL in the coat (Soluplus®) was limited to 25% DS, giving 
rise to a torque value of 70% motor load and a die pressure of 33 bar. Above these values, the 
extruder torque was too high and the extrudates had a rough surface. Possibly MDL can be 
increased by processing at a higher extrusion temperature, but as this increases the risk of 
drug degradation, higher extrusion temperatures were not explored in this study. Extrusion of 
formulations with a core composed of polycaprolactone and a coat consisting of PEO/PEG 
(1/1) was performed at 70, 95 and 120 °C. The MDL at each temperature was determined, 
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also taking into account the dimensions of the die. Using a die with a core diameter of 3 mm 
and a coat thickness of 0.5 mm, the MDL in the core/coat system was 40%/30%, 50%/50% 
and 60%/50% at an extrusion temperature of 70, 95 and 120 °C, respectively. The 
corresponding torque values were 80/40%, 75/30%, 60/25% and the observed melt pressure 
was 50/75, 30/50, 15/40 bar. Using a die with a core diameter of 2 mm surrounded by a coat 
of 1 mm thickness, the MDL in core/coat at 70 °C, 95 °C and 120 °C was 10%/20%, 
40%/40% and 50%/50%, respectively. The corresponding torque values were 85/40%, 
75/35%, 60/35% and the observed melt pressure was 90/80, 60/80, 60/65 bar. The MDL in the 
core (processed at a specific extrusion temperature) was lower using a die with a core-
diameter of 2 mm compared to a 3 mm diameter, since the cross sectional area decreased by 
more than half (7 mm2 to 3.1 mm2) leading to higher die pressures. On the contrary, the MDL 
in the coat was higher using a die with a coat-thickness of 0.5 mm compared to a 1 mm 
thickness given that although the cross sectional area increased (5.6 mm2 to 9.5 mm2) a higher 
feed rate (600 g/h, vs. 150 g/h) was required to manufacture the co-extrudates, resulting in a 
higher die pressure at lower drug concentrations.  
All co-extruded formulations were characterized by XRD directly after preparation 
(Fig. 3 and 4). The X-ray patterns of the formulation composed of ethylcellulose (core) and 
Soluplus® (coat) exhibited crystalline peaks corresponding to DS with an intensity 
comparable to those in the physical mixtures, indicating that most of the drug had maintained 
its crystalline state in the co-extrudates. However DSC (data not shown) revealed that a 
limited amount of DS (±10%) was solubilized in Soluplus® during extrusion, which could 
compromise the long term stability of the coat of this co-extruded formulation due to 
recrystallization. Yet no recrystallization was observed during 12 months storage at room 
temperature. The co-extruded formulations composed of polycaprolactone (core) and 
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PEO/PEG (coat) contained crystalline DS. These results were confirmed with DSC (data not 
shown). 
 
Figure 3a. X-ray diffraction pattern of (A) DS, (B) ethylcellulose/DBS (4/1), (C) physical 
mixture and (D) core of co-extrudate composed of 60/32/8% DS/ethylcellulose/DBS. 
 
 
Figure 3b. X-ray diffraction pattern of (E) DS, (F) PLUR, (G) Soluplus®, (H) physical 
mixture and (I) coat of co-extrudate composed of 25/67.5/7.5% DS/Soluplus®/PLUR. 
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Figure 4a. X-ray diffraction pattern of (A) DS, (B) polycaprolactone, (C) physical mixture 
and (D) core of co-extrudate composed of 60/40% DS/polycaprolactone. 
 
 
Figure 4b. X-ray diffraction pattern of (E) DS, (F) PEO/PEG (1:1), (G) physical mixture and 
(H) coat of co-extrudate composed of 22.5/38.75/38.75% HCT/PEO/PEG.  
 
The adhesion force between core and coat in the co-extruded formulations was 
measured. For the formulation composed of an ethylcellulose core and a Soluplus® coat (F1) 
no accurate values could be obtained, as the coat tended to fracture before of its separation 
from the core. Nonetheless, there seemed to be good adhesion as no delamination could be 
observed. The adhesion force of formulations composed of polycaprolactone (core), 
PEO/PEG (coat) and different DS concentrations extruded at different temperatures (F5-F12, 
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Table 2) was measured to investigate the influence of drug load and extrusion temperature on 
core/coat adhesion (Table 3). The adhesion force increased with increasing extrusion 
temperature (except for the formulation without DS extruded at 95 and 120 °C) as this 
allowed more polymer entanglement at the interface. Although polycaprolactone and 
polyethylene oxide are immiscible [6] adhesion between these two polymers is possible, 
mainly caused by entanglements at the interphase and to a lesser extent by van der Waals or 
hydrogen-bonding interactions. As the extrusion temperature increased, the width of the 
interface between core and coat decreased (Fig. 5a) and the adhesion force increased, possibly 
attributed to an increased number of entanglements at higher temperature [7]. Unexpectedly 
we found that adhesion force was also influenced by drug load. There was almost no adhesion 
between the two pure polymer layers (without DS), while a significantly higher adhesion 
force was noticed for the formulations containing 30 and 50% of drug, irrespective of the 
extrusion temperature. Since the drug was mainly present in its crystalline form, it was 
unlikely that the improved adhesion was attributed to chemical interactions. Microscopic 
inspection (Fig. 5b) of the formulations with different drug loads (0, 30 and 50% DS) 
extruded at the same temperature (120 °C) revealed that with increasing drug load the surface 
of core and coat became rougher, which was probably resulted in the enhanced adhesion. 
Roughening of surfaces can improve adhesion through mechanical interlocking or by 
increasing the physical area of contact, thus enabling more interfacial interactions [8].  
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Table 3. Mean adhesion force in N (±S.D.) between core and coat in function of drug load 
(0%, 30%, 50%) and extrusion temperature (70, 95, 120 °C). 
70 °C 95 °C 120 °C 
0% DS 0.6 ± 0.7a’ 5.2 ± 2.3b’ 3.4 ± 2.2c’ 
30% DS 14.7 ± 5.8a” 25.1 ± 5.3b” 30.6 ± 7.8b” 
50% DS --- 30.1 ± 5.4b” 39.3 ± 7.1c” 
a,b,c means in the same row with different superscript are different at the 0.05 level of significance. 
‘,” means in the same column with different superscript are different at the 0.05 level of significance. 
 
 
Figure 5a. SEM images of the coat/core interface of co-extruded formulations composed of 
polycaprolactone (core), PEO/PEG (ratio: 1/1) (coat) extruded at (A) 95 °C and (B) 120 °C 
(magnification 500x). 
  
Co-extrusion as manufacturing technique for multilayer mini-
matrices with dual drug release CHAPTER 3 
 
100 
 
 
Figure 5b. SEM images of the core (at coat/core interface) of co-extruded formulations 
composed of polycaprolactone (core), PEO/PEG (ratio: 1/1) (coat) and a DS concentration of 
(A) 0%, (B) 30%, (C) 50% (magnification 1000x). 
 
The in vitro release profiles of four experimental formulations (F1-F4) and the 
reference formulation are shown in Fig. 6. The coat of all experimental co-extruded 
formulations rapidly dissolved (±20 min) in the dissolution medium, through which the DS 
release from the core was hardly obstructed. All formulations showed an initial burst release 
(39, 37, 63 and 84% DS released in 1 h from F1, F2, F3 and F4), followed by a sustained DS 
release. The initial burst was mainly caused by the immediate release of the entire drug 
fraction in the coat, plus a small fraction already released from the core. The remaining DS 
fraction was sustained released from the core. Full drug release was observed after 24 h for all 
experimental formulations. After 12 months storage at room temperature, all dissolution 
profiles were identical. 
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Figure 6. Mean dissolution profile (±S.D.) (n = 3) of experimental formulations (●) F1, (X) 
F2, (▲) F3, ( ) F4 and (---) Motifene®. 
 
 
3.3. Bioavailability  
Fig. 7 shows the mean plasma concentration-time profiles after oral administration of 
100 mg DS as experimental mini-matrices (F2-F4) and Motifene®. The Motifene® capsules 
contain 33% IR pellets (Eudragit® L) and 67% SR pellets (Eudragit® RS and RL). According 
to the dissolution data (Fig. 6), all test formulations as well as the reference formulation 
provided dual DS release: immediate drug release from the coat and sustained release over 
24h from the core. The differences in in vitro release between formulations F2-F4 were caused 
by a variable DS ratio in the core/coat combination and were also reflected in the in vivo 
behavior: formulations with a higher DS ratio in coat/core resulted in higher initial plasma 
concentrations (Fig. 7). The pharmacokinetic parameters are reported in Table 4. In order to 
examine the contribution of the coat and the core separately, Cmax and Tmax are reported for 
the initial part as well as for the latter part of the bioavailability curve. 
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Figure 7. Mean DS plasma concentration-time profiles (± SD, n = 6) after oral administration 
of 100 mg diclofenac sodium to dogs as experimental formulation composed of a 
polycaprolactone core and a PEO/PEG (ratio 1/1) coat (F2-F4) or as reference formulation: (X) 
F2 (coat: 30 mg DS; core: 70 mg DS), (▲) F3 (coat: 43 mg DS; core: 57 mg DS), () F4 (coat: 
75 mg DS; core: 25 mg DS), (- - -) Motifene® (IR pellets: 33 mg DS; SR pellets: 67 mg DS). 
 
Table 4. Mean pharmacokinetic parameters (±S.D.) after oral administration of 100 mg 
diclofenac sodium to dogs as F2, F3, F4 or as reference formulation (Motifene®). 
 
Cmax1 (μg/ml) Cmax2 (μg/ml) Tmax1 (h) Tmax2 (h) AUC (μg.h/ml) 
F2 2.2 ± 1.3 2.4 ± 0.7 1.7 ± 0.3 2.75 ± 0.9a 9.2 ± 2.3a 
F3 2.4 ± 1.4 2.3 ± 1.3 1.5 ± 0.4 4.8 ± 1.0 12.8 ± 1.5a 
F4 5.4 ± 3.7 4.1 ± 2.9 1.5 ± 0.9 3.8 ± 0.4 20.4 ± 3.1b 
Motifene® 0.9 ± 0.5 2.1 ± 1.6 2.4 ± 1.8 5.5 ± 1.4b 10.9 ± 5.6a  
a,b means in the same column with different superscript are different at the 0.05 level of significance. 
 
Co-extrusion as manufacturing technique for multilayer mini-
matrices with dual drug release CHAPTER 3 
 
103 
 
Oral administration of formulation F4 resulted in a significantly higher AUC value 
compared to formulations F2, F3 and the reference formulation. Fig. 8 represents the AUC 
values of each dog separately after administration of formulations F2-F4 and the reference 
formulation. The variability in AUC values was higher after administration of the reference 
formulation than for all test formulations. This was probably due to the fact that the IR 
Motifene® pellets contained Eudragit® L, which only started to dissolve above pH 5. As 
mentioned in the introduction, enteric coated formulations show more variation in lag-time 
and time to peak plasma concentration [1]. Although only F4 was significantly different from 
the other formulations, the AUC values tended to increase at higher DS concentration in the 
coat. The higher bioavailability of F4 correlated well with the faster drug release rate in vitro. 
Diclofenac sodium, as a class II drug in the Biopharmaceutical Classification System with a 
high permeability and low solubility, is known to be absorbed well throughout the intestinal 
tract. However, the main site for the absorption of DS is considered to be the small intestine. 
For less soluble drugs, the drug release rate is influenced by the water content in the GI tract. 
Due to the low water content and GI motility in the colon, the drug dissolution and as a 
consequence the DS absorption in the colon is limited. The lower fraction of F2, F3 and the 
reference formulation absorbed in dogs in comparison to F4 probably resulted from the 
incomplete drug release of DS in the upper GI tract owing to the short small intestine transit 
time and the low drug release in the colon because of its low solubility [9]. The dominant role 
of the upper GI tract in DS absorption was also demonstrated by the fact that F2, F3 and the 
reference formulation yielded comparable AUC numbers. Although between 2 and 24 h the 
dissolution profiles of F3 and reference were uniquely different from F2, during the first 2 h 
the release from the reference was intermediate to F2 and F3.  
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Figure 8. Comparison of AUC level of DS after oral administration of experimental co-
extruded (F2, F3 and F4) and reference formulation (Motifene®) to dogs. 
 
No significant differences were found in Cmax1, Cmax2 and Tmax1 values between all 
experimental formulations and the reference formulation (p > 0.05). Cave: statistics were 
influenced by the fact that 2 dogs showed limited drug absorption. Tmax2 of F2 was 
significantly lower than that of the reference formulation (p < 0.05), whereas no significant 
differences with the other formulations were seen (p > 0.05). The distinction between F2 and 
the reference was probably due to the difference in drug release rate. Initially DS was released 
fast from both formulations, however the rate of DS release from formulation F2 already 
dropped after 2 h while for the reference formulation it stayed high until 4 h after 
administration. 
 
4. Conclusions 
Co-extrusion proved to be a promising technique to produce in a single step multilayer 
mini-matrices with dual drug release. Core/coat dosage forms were developed using two 
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different polymer combinations (ethylcellulose/Soluplus® and polycaprolactone/PEO). Co-
extruded formulations composed of polycaprolactone (core) and PEO/PEG (coat) were 
preferable because they allowed extrusion at a lower temperature and they provided better 
mechanical properties. Furthermore, the adhesion force between the two layers depended on 
extrusion temperature and drug load. By varying the DS ratio in coat and core, the in vitro and 
in vivo drug release could be controlled, demonstrating the flexibility of the dosage form. 
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1. Introduction 
Hot-melt extrusion (HME) shows numerous benefits over traditional methods including 
the continuity of the production process, environmental advantages due to elimination of 
solvents and the possibility of improving drug solubility. The latter has drawn attention because 
large numbers of new chemical entities under development exhibit very poor solubility and 
bioavailability. Formulation of solid solutions via HME can be an efficient approach in the 
delivery of poorly water-soluble drugs. Co-extrusion is gaining importance for the production of 
oral drug products as combination therapy is becoming increasingly important as fixed-dose 
combination (FDC) products offer therapeutic (improved patient adherence) and economic 
(lower manufacturing costs) benefits. Such “polypills” are being used in the treatment of e.g. 
cardiovascular disease, diabetes, hyperlipidemia, HIV, tuberculosis and malaria. In this study 
acetylsalicylic acid (ASA, an anticoagulant) and fenofibrate (FF, a lipid regulating drug) were 
incorporated as hydrophilic and hydrophobic model drugs, respectively. While ASA is slightly 
soluble in water and has relatively high oral bioavailability, FF is poorly water-soluble and has a 
low bioavailability after oral administration. Due to their biopharmaceutical and pharmacological 
properties, immediate release of both drugs is required. The aim of this study is to design a 
core/coat dosage form suitable for co-extrusion, whereby the core and coat formulation provide 
immediate drug release (IR) of both drugs (ASA and FF). Several research groups have already 
investigated the feasibility of HME to produce immediate release FF dosage forms. Kollidon® 
VA 64 [1, 2], Eudragit® E PO [2], Soluplus® [3] and blends of PVPVA 64, HPMC and 
Soluplus® [4] were reported.   
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2. Materials and methods 
2.1. Materials 
The following polymers were used during the polymer selection procedure: Eudragit® E 
PO (Evonik, Darmstadt, Germany), SentryTM Polyox® WSR N10 (polyethylene oxide, PEO 
100,000 g/mol, Colorcon, Dartford Kent, United Kingdom), Soluplus®, Kollidon® VA 64, PF 12 
and 30 (BASF, Ludwigshafen, Germany). Polyethylene glycol (PEG 4000 g/mol, Fagron, 
Waregem, Belgium) and Pluronic® F-68 (PLUR, Sigma–Aldrich, Steinheim, Germany) were 
used as plasticizers. Fenofibrate (FF, Roig-Farma, Barcelona, Spain) and acetylsalicylic acid 
(ASA, Utag, Amsterdam, The Netherlands) were incorporated as hydrophobic and hydrophilic 
model drug, respectively. . Their relevant physico-chemical properties are listed in Table 1. All 
other chemicals were of analytical grade. 
 
Table 1. Physico-chemical properties of fenofibrate and acetylsalicylic acid. 
Properties Structural formula 
Name fenofibrate 
Melting point  81 °C 
Degradation temperature >200 °C [5] 
Solubility in water practically insoluble in water [6] 
Log P 5.24 
   
Name acetylsalicylic acid 
 
Melting point  144 °C 
Degradation temperature 140 °C [7] 
Solubility in water slightly soluble in water [6] 
pKa 3.5  
Log P 1.4  
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2.2. Polymer selection 
For the selection procedure several thermoplastic polymers were hot-melt extruded and 
evaluated for processability, macroscopic properties (visual inspection of surface, die swell 
quantification using marking gauge), salicylic acid content (ASA formulations) and in vitro drug 
release. Polymers/plasticizer were mixed (with mortar and pestle) with FF and ASA 
(concentration range: 20-40%, w/w) and hot-melt extruded using a co-rotating, fully 
intermeshing twin screw extruder (Prism Eurolab 16, ThermoFisher Scientific, Germany) having 
a length-to-diameter ratio of 25/1. The co-rotating screws consisted of three mixing sections and 
a densification zone. A co-extrusion die (Guill, West Warwick, USA) was connected at the end 
of the extruder. The extrusion temperature varied according to the polymer, but all five heating 
segments of the extruder were set at the same temperature, except for the first heating zone 
which was set at 70 °C to avoid sticking of the powder in the feed section. The premixes were 
fed (feed rate: 300 g/h) into the extruder using a loss-in-weight powder feeder (Brabender 
flexwall®, Duisburg, Germany). The screw speed was kept constant at 120 rpm and 180 rpm for 
extrusion of ASA and FF formulations, respectively. ASA formulations were extruded through 
the core orifice of the co-extrusion die, yielding extrudates with a diameter of 2 mm. FF 
formulations were extruded through the coat orifice (1mm coat thickness) yielding hollow 
cylindrical tubes with an outer and inner diameter of 4 and 2 mm, respectively. After cooling 
down to room temperature, the cylindrical extrudates were manually cut into mini-matrices of 2 
mm length.  
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2.3. Production of co-extrudates 
Polymer/plasticizer and drug were premixed in a tumbling mixer (Turbula® T2A, W.A. 
Bachofen, Basel, Switzerland) for 20 min. Co-extrusion was performed using two co-rotating, 
fully intermeshing twin screw extruders (Prism Eurolab 16, ThermoFisher Scientific, Germany). 
The multimanifold co-extrusion die (Guill, West Warwick, USA) was connected to both 
extruders. Both melts were combined in the die to form two concentric layers, a core and a coat. 
All five heating segments of both extruders were set at the same temperature, except for the first 
heating zone which was set at 70 °C to avoid sticking of the powder in the feed section. The 
premixes were fed into the corresponding extruders using loss-in-weight powder feeders 
(Brabender Flexwall®, Duisburg, Germany). The screw speed was kept constant at 120 rpm 
(core) and 180 rpm (coat). The co-extrusion die was designed with a core diameter of 2 mm and 
a coat thickness of 1 mm, resulting in a total die diameter of 4 mm. After cooling down to room 
temperature, the cylindrical co-extrudates were manually cut into mini-matrices of 2 mm length.  
 
2.4. Determination of free salicylic acid 
The salicylic acid (SA) content in the extrudates was assessed according to the USP 32 
monograph for aspirin tablets.  
 
2.5. In vitro drug release 
Dissolution studies were performed using USP apparatus 1 (baskets). The equipment 
consisted of a VK 7010 dissolution system combined with a VK 8000 automatic sampling 
station (VanKel Industries, NJ, USA). Acetate buffer pH 4.5 containing 0.05 M sodium lauryl 
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sulfate was used as dissolution medium [8, 9]. Sink conditions were maintained during the 
experiments. The temperature of the dissolution medium (900 ml) was kept constant at 37 ± 0.5 
°C. The rotational speed of the baskets was set to 100 rpm. Samples (5 ml) were withdrawn at 5, 
10, 15, 20, 30, 45, 60 (and 90) min.  
ASA and FF concentrations were determined using a validated HPLC method. The HPLC 
equipment (Merck-Hitachi, Darmstadt, Germany) consisted of a gradient solvent pump set at a 
constant flow rate of 1 ml/min, an autosampler, a reversed-phase C-18 column (LiChrospher® 
100 RP-18 (5 μm)) (250 x 4 mm) and guard column (4 x 4 mm) and a UV detector set at 285 nm. 
The injection volume was 20 µl. An automatic integration system (software D-7000 Multi-
Manager) was used for peak integration. The mobile phase consisted of mixtures of buffer 
solution pH 2.9 [9] and methanol: initially using a 57:43-ratio (to elute ASA and SA, while FF 
was retained on the column). After 14.5 min the ratio of the mobile phase was rapidly changed to 
10:90 (to elute the hydrophobic FF from the column), after 22.0 min the ratio between the 
aqueous and organic phase was again set at 57:43 and the column was equilibrated until 31.0 min 
prior to the following analysis.  
 
2.6. X-ray diffraction 
X-ray diffraction (XRD) was performed to investigate the crystallinity of the drugs in the 
mini-matrices. X-ray patterns of drug, polymer, physical mixtures and extrudates were obtained 
using a D5000 Cu Kα Diffractor (λ = 0.154 nm) (Siemens, Karlsruhe, Germany). The angular 
range (2θ) varied from 10° to 60° (step width = 0.02°, counting time = 1 s/step). 
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2.7. Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was used to study the solid state properties of 
the extrudates. The thermal behavior of the individual components, physical mixtures and 
extrudates was evaluated using a Q2000 DSC (TA Instruments, Leatherhead, UK). The system 
was equipped with a refrigerated cooling system. Samples (5-10 mg) were accurately weighed 
and hermetically sealed in aluminum pans (TA Instruments, Leatherhead, UK).They were cooled 
to -70 °C, followed by heating to 170 °C at a linear heating rate of 10 °C/min. 
 
2.8. Scanning electron microscopy 
Scanning electron microscopy (SEM) was used to visualize the interface between both 
co-extruded layers. Samples were coated with platinum by means of a sputter coater (Auto Fine 
Coater, JFC-1300, Jeol, Tokyo, Japan). Photomicrographs were taken with a scanning electron 
microscope (Jeol JSM 5600 LV, Jeol, Tokyo, Japan).  
 
2.9. Raman spectroscopy 
The distribution of the different components in the coat and core of the co-extrudates was 
evaluated with Raman microscopic mapping using a Raman Rxn1 Microprobe (Kaiser Optical 
Systems Inc., Ann Arbor, MI, USA), equipped with an air-cooled CCD detector. The laser 
wavelength employed was 785 nm from a Invictus NIR diode laser (Kaiser Optical Systems Inc., 
Ann Arbor, MI, USA). All spectra were recorded with a resolution of 4 cm−1 and an exposure 
time of 7 s, using a laser power of 400 mW. Cross sections of co-extrudates were scanned by a 
50× short working distance objective lens (spot size 10 µm) in point-by-point mapping mode 
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using a step size of 10 µm in both the x and y directions. The resulting images provide 
information about the distribution of different components in the co-extrudates. Data collection 
and data transfer were automated using the HoloGRAMSTM data collection software (version 
2.3.5, Kaiser Optical Systems Inc., Ann Arbor, MI, USA). The analysis of the spectra was done 
using HoloMAPTM data analysis software (version 2.3.5, Kaiser Optical Systems Inc., Ann 
Arbor, MI, USA) and Matlab® software (version 7.1, The MathWorks Inc., Natick, MA, USA). 
All spectra were baseline corrected using the Pearsons method. To visualize the distribution of 
the drug within the co-extrudate, a specific peak of each drug was shown relatively to a specific 
peak of the polymer. In order to attribute specific Raman peaks in the spectra to the different 
components in the formulations, Raman spectra were collected from the pure components and 
the separate layers. All spectra were recorded with a resolution of 4 cm−1 and an exposure time 
of 10 s. Standard normal variate (SNV) pre-processing was applied on the collected spectra prior 
to analysis, to correct for the variation in path length/sampling distance between probe and 
sample.  
 
2.10. Karl Fisher titration 
The moisture content of the polymers and plasticizers at ambient conditions was determined by 
volumetric Karl Fischer titration using a V30 volumetric KF titrator (Mettler Toledo, USA). The 
experiments were performed in triplicate. 
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3. Results and discussion 
3.1. Polymer selection  
The aim of this work was to develop a formulation providing immediate release from a 
co-extruded dosage form, containing ASA as hydrophilic model drug and FF as hydrophobic 
model drug. Several thermoplastic polymers were therefore hot-melt extruded in combination 
with ASA and FF, and evaluated for processability (torque and die pressure), macroscopic 
properties (surface, transparency, consistency and die swell), ASA decomposition (via SA 
content determination) and in vitro drug release. Polymers that failed one criterion, i.e. were not 
processable below 140 °C with a torque value of <80% motor load and a die pressure of <100 
bar, exhibited unfavorable macroscopic properties (irregular surface, sticky, irregular 
dimensions), contained >3% SA or did not release 80% of the drug in approximately 45 min, 
were rejected.  
 
3.1.1. ASA 
Five polymers (PEO, Eudragit® E PO, Soluplus®, Kollidon® VA 64 and Kollidon® PF 12) 
were tested during ASA-polymer screening. Table 2 presents the composition, extrusion 
temperature, SA content and in vitro drug release of the screened formulations. All polymers 
were processable via hot melt extrusion at the specified temperatures. All PEO/ASA extrudates 
(extruded at 75 °C) were smooth, slightly yellow and transparent. However, they became opaque 
after cooling down to room temperature as PEO recrystallized. Process monitoring revealed that 
the addition of PEG 4000 as a plasticizer resulted in lower die pressures and torque values. 
Unplasticized Eudragit® E PO/ASA mixtures had a minimum extrusion temperature of 140 °C. 
The incorporation of PEG 4000 improved processing by lowering the extruder torque and die 
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pressure. The addition of 25% PEG allowed extrusion at 120 °C. Eudragit® E PO/ASA 
extrudates were slightly yellow but transparent. They exhibited unfavorable macroscopic 
properties as they were very flexible and sticky. Extrusion of pure Soluplus® requires a 
temperature of 140 °C. Soluplus®/ASA mixtures were processable at a minimum temperature of 
110 °C and good quality extrudates (smooth, clear, rigid, not sticky) were obtained, but with a 
slight pink discoloration. This discoloration was probably due to the formation of complexes 
between salicylic acid (ASA degradation) and free iron ions originating from the extrusion 
screws or barrel due to shear [10]. The addition of 1% sodium EDTA eliminated the pink 
discoloration, which supported our hypothesis. For the processing of Kollidon® VA 64/ASA 
extrudates a temperature of at least 130 °C was required. The extrudates were clear and smooth 
but the same pink discoloration as seen with Soluplus® appeared. Again, the problem was solved 
by adding 1% sodium EDTA. Kollidon® PF 12 was processable at a temperature of 110 °C. The 
quality of all Kollidon® PF 12/ASA extrudates was good (clear, rigid) and no discoloration was 
noticed. It was found in literature that Kollidon® forms complexes in solution with salicylic acid, 
which could be a possible explanation for the absence of the pink discoloration [11]. No 
significant die swell was observed for any of the tested polymers. 
 
Table 2. Overview of polymer screening results for ASA. 
Carrier ASA (%) Tdie - Textrusion* (°C) SA content (%)  Complete release (min) 
PEO (0-50 % PEG)  20 75 - 75 26.6 (± 0.17) -12.0 (± 0.23)  not tested*** 
Eudragit® E PO (0-25% PEG) 20 120 - 140-120   not tested** not tested** 
Soluplus®  20  95 - 110  4.7 (± 0.21) not tested*** 
Kollidon® VA 64  20 105 - 130  2.4 (± 0.11) 20 
Kollidon® PF 12  20 95 - 110 1.5 (± 0.16) 10 
*: lowest extrusion temperature usable resulting in a torque value of <80% motor load and a pressure of <100 bar. 
**: too sticky and highly flexible  
***: SA content >3% 
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ASA undergoes thermal decomposition as is starts to decompose upon melting (140 °C) 
[7], while in the presence of water hydrolysis of ASA results in the formation of SA and acetic 
acid. Therefore the polymers that yielded good quality extrudates (PEO, Soluplus®, Kollidon® 
VA 64 and Kollidon® PF 12), were further tested for salicylic acid content (Table 2). The USP 
SA limits [8] for ASA tablets (≤0,3%) or coated ASA tablets (≤3%) were used as reference 
values, although solid dispersions do not comply with either dosage forms. For all PEO/ASA 
formulations a large amount of SA was formed during extrusion. It was found that the SA 
content decreased (26.6, 17.8, 12.0% SA) with increasing PEG concentration (0, 25, 50% PEG) 
and decreasing torque (60, 30, 15% motor load) and die pressure (55, 30, 13 bar). Breitenbach 
[12] stated that high shear forces can lead to a local temperature increase within the extrusion 
barrel. In addition, Breitenbach identified the residence time and die pressure as factors with a 
significant impact on the impurity profile. These findings support our hypothesis that the 
extruder torque and die pressure may play a role in ASA degradation during extrusion. The 
degree of decomposition in extrudates with Soluplus® as carrier was lower in comparison with 
PEO formulations, as it was possible to approach the USP limit of ≤3%. Nevertheless, the only 
two polymers that complied with the SA limit were Kollidon® VA 64 and Kollidon® PF 12, 
containing 2.4 and 1.5% SA respectively. Kollidon® VA 64 and Kollidon® PF 12, the polymers 
that complied with the criteria of processability and ASA stability, were tested for in vitro drug 
release. The ASA release from Kollidon® VA 64 was complete in 20 min, whereas the release 
from Kollidon® PF 12 was already complete in 10 min.  
 
3.1.2. FF 
Five polymers (PEO, Soluplus®, Eudragit® E PO, Kollidon® VA 64 and Kollidon® 30) 
were tested as FF carriers. Due to the plasticizing properties of FF, Kollidon® PF 12 (used during 
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ASA polymer screening) was replaced by Kollidon® 30 exhibiting a higher Tg (149 °C instead of 
90 °C). Table 3 presents the composition, extrusion temperature and in vitro drug release of the 
screened formulations. All polymers were processable via hot-melt extrusion at the specified 
temperatures. Unplasticized PEO/FF mixtures had a minimum extrusion temperature of 100 °C 
as the die pressure exceeded 100 bar at lower process temperatures. PEO/PEG/FF mixtures could 
be extruded at 75 °C, although torque and die pressure increased at lower PEG concentration. 
Soluplus® (loaded with 20-30% FF) was processable at a temperature of 100 °C. Apparently, an 
increase in FF concentration (20-30% FF) improved the ease of processing by lowering the Tg 
(from 30.0 to 15.0 °C). FF melted during processing since the process temperature (100 °C) 
exceeded its melting point (80 °C). All Soluplus® extrudates exhibited a smooth surface. All 
extrudates up to 30% FF were transparent. Eudragit® E PO (loaded with 20% FF) was 
processable at a temperature of 120 °C without the addition of a plasticizer. Increasing FF 
concentrations improved the ease of processing by lowering the extruder torque and die pressure. 
Consequently the extrusion temperature of mixtures containing 30% and 40% FF was lowered to 
110°C and 100°C, respectively. All Eudragit® E PO/FF extrudates were transparent when they 
emerged from the die. However, the extrudates had unfavorable properties as they were sticky 
and collapsed after cooling down to room temperature. Kollidon® VA 64/FF mixtures (20-40% 
FF) were processable between 100 and 130 °C. As observed for Soluplus® and Eudragit® E PO, 
the ease of processing enhanced at increasing FF loads. Clear extrudates with good quality (no 
die swell, thin, smooth, clear and rigid) were obtained. Kollidon® 30 loaded with 30% FF was 
extrudable at 150 °C. Increasing the drug load to 40% slightly enhanced the processability. 
However, the minimal extrusion temperature remained 150 °C as the die pressure increased 
sharply at lower temperature. All extrudates were clear during extrusion and remained clear after 
cooling down to room temperature. Good quality extrudates (no die swell, rigid, clear and a 
smooth surface) were obtained.  
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Table 3. Overview of polymer screening results for FF. 
Carrier FF (%) Tdie-Textrusion (°C)* Complete release (min) 
PEO (0-50 % PEG) 20 75 - 100-75 >60  
Soluplus®  20-30 100 - 100 ±60 
Eudragit® E PO 20-40 100 - 120-100 not tested** 
Kollidon® VA 64 20 105 - 130 20 
 30-40 100 - 100 20 
Kollidon® 30 30-40 125 - 150 20 
*: lowest extrusion temperature usable resulting in a torque value of <80% motor load and a pressure of <100 bar. 
**: too sticky and highly flexible 
 
 
The polymers that yielded good quality extrudates were further tested for in vitro drug 
release (data not shown). The time required for complete FF release from the different 
formulations is shown in Table 3. FF release from PEO extrudates was incomplete after 1 h. 
Although the addition of PEG to PEO resulted in a considerable increase in release rate, the drug 
release rate remained too low. FF release from Soluplus® extrudates was nearly complete after 1 
h. A higher drug load did not influence the release rate significantly. Although Soluplus® offers 
the particular advantage that precipitation and crystallization of drugs during dissolution is 
prevented as a result of its micellar character [13], the FF release rate was lower than expected. 
Hughey et al. described that Soluplus® tended to form a strong gel (in vitro) and that dissolution 
occurred through erosion of the matrix [14]. Recently, Soluplus® was also found to tailor (delay) 
the release of another hydrophilic drug (acetaminophen) [15]. Complete FF release from all 
formulations formulated with Kollidon® VA 64 and Kollidon® 30 was achieved within 20 min.  
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3.2. Co-extrusion 
A successful co-extrusion process requires that both melts flow through the co-extrusion 
die under the same temperature conditions. Based on the polymer screening data, the following 
formulations were identified as potentially useful for co-extrusion: Soluplus®, Kollidon® VA 64 
and Kollidon® 30 as FF carriers (coat) in combination with Kollidon® VA 64 or Kollidon® PF 12 
as ASA carriers (core). The ASA:FF ratio in all formulations was 35:65, which complied with 
the ratio of 80 mg ASA and 145 mg FF (usual daily dose). As the coat had a total volume of ±19 
mm3 versus ±6 mm3 for the core, FF was formulated in the coat. The content of ASA and FF in 
the co-extrudates was ensured by setting correct combinations of feed rate and drug load in both 
processes. 
The combination of Kollidon® 30 as carrier for FF with Kollidon® VA 64 or Kollidon® 
PF 12 as carriers for ASA failed in terms of processability. Using the minimum possible die 
temperature for Kollidon® 30 (125 °C) the core formulations with Kollidon® VA 64 and 
Kollidon® PF 12 were too liquid as they left the die resulting in collapse during cooling down to 
room temperature. The co-extrusion trials showed that Kollidon® VA 64 and Kollidon® PF 12 as 
carrier for ASA were compatible with Kollidon® VA 64 and Soluplus® as carrier for FF in terms 
of extrusion temperature. The composition as well as the extrusion conditions used for each 
formulation are shown in Table 4. The core and coat of co-extrudate F2 were processable at the 
same temperature (barrel: 130 °C, die: 105 °C). As the core and coat of F1, F3 and F4 had 
different extrusion temperatures (cfr. polymer selection), temperature adjustments were required 
to enable the co-extrusion of these formulations. Nevertheless, all four formulations had good 
macroscopic properties as they were transparent and exhibited no die swell. Furthermore, both 
layers adhered firmly as no delamination was observed (Fig. 1).  
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Table 4. Composition and extrusion parameters of co-extruded formulations. 
 Carrier Drug concentration (%) Extrusion temperature (°C) Feed rate (g/h) 
 Core Coat Core (ASA) Coat (FF) Core Coat Die Core Coat 
F1 Kollidon® PF 12 Kollidon® VA 64 20 20 120 130 95 300 545 
F2 Kollidon® VA 64 Kollidon® VA 64 20 20 130 130 105 300 545 
F3 Kollidon® PF 12 Soluplus® 20 20 120 100 95 300 545 
F4 Kollidon® VA 64 Soluplus® 20 20 130 105 105 300 545 
 
 
 
Figure 1. SEM images of co-extruded formulations (Table 4). Core/coat interface is marked by 
the white arrow. 
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In addition, the thickness of the coat and core was uniform, as confirmed with a marking 
gauge. After extrusion, the core and coat of the co-extrudates were physico-chemically 
characterized. The thermogram of all coat formulations revealed that there was no crystalline FF 
present in formulation F1, F2 (Fig. 2A), F3 and F4 (Fig. 2B). For all formulations, a single glass 
transition temperature (44.80 °C (F1 and F2), 32.73 °C (F3 and F4)) was detected, lying in 
between the individual glass transitions of FF (-21 °C) and Kollidon® VA 64 (101 °C) or 
Soluplus® (70 °C). This indicated the presence of a molecular dispersion. The DSC thermogram 
of ASA showed a melting peak at 144.18 °C (Fig. 3). This peak was absent in the thermogram of 
all core formulations, indicating the loss of crystallinity of ASA in the core of the co-extrudates. 
Since the melting point of ASA was never reached during the extrusion process, this indicated 
that ASA had dissolved in the matrices. A single glass transition temperature (30.15 °C (F1 and 
F3), 39.71 °C (F2 and F4)) was detected, lying in between the individual glass transitions of ASA 
(-30 °C) and Kollidon® PF 12 (90 °C) or Kollidon® VA 64 (101 °C). These results were 
confirmed with XRD (data not shown). The SA content in all core formulations 1.7 ± 0.12 for F1 
and F3 and 2.3 ± 0.29 for F2 and F4 was in agreement with those found during the polymer 
screening tests (Table 2). 
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:  
Figure 2. Solid state characterization (DSC) of coat of co-extrudated formulations: (A) 20% FF 
in Kollidon® VA 64 (F1, F2) and (B) 20% FF in Soluplus® (F3 ,F4). Within each figure from top 
to bottom: FF, carrier (Kollidon® VA 64 (A), Soluplus® (B)), physical mixture and extruded coat 
formulation. 
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Figure 3. Solid state characterization (DSC) of core of co-extrudated formulations: (A) 20% 
ASA in Kollidon® PF 12 (F1, F3) and (B) 20% ASA in Kollidon® VA 64 (F2 ,F4). Within each 
figure from top to bottom: ASA, carrier (Kollidon® PF 12 (A), Kollidon® VA 64 (B)), physical 
mixture and extruded core formulation.   
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To evaluate the drug distribution in core and coat, Raman microscopic mapping was 
performed. The peak intensity of the Raman band of ASA in the 745-760 cm−1 region was 
monitored to map the ASA distribution in the core and to check if migration of ASA to the coat 
of the co-extrudates had occurred during co-extrusion. Likewise, the FF distribution in coat and 
core was mapped by monitoring the peak intensity of the Raman band of FF in the 760-778 cm−1 
region. Fig. 4 shows the distribution of ASA throughout co-extruded formulation F1. A red color 
corresponds to a high peak intensity, indicating a high ASA concentration, while a blue color 
corresponds to a low ASA concentration. The ASA band in the 745-760 cm−1 region showed an 
intense peak in the core. A very low peak intensity was found in the coat at the interface with the 
core (light blue), indicating very little migration of ASA to the coat. Comparing the Raman 
spectra of the light blue area with those of the individual drugs (Fig. 5), it was demonstrated that 
the light blue area contained both drugs. The FF band in the 760-778 cm−1 region showed an 
intense peak in the coat and not in the core. However, a low FF peak intensity was found in the 
core at the interface with the coat (yellow), indicating very little migration of FF in the core. 
Comparing the Raman spectra of the yellow area with those of the individual drugs (Fig. 5), it 
was demonstrated that the yellow area contains both drugs. The mapping results of all other 
formulations were similar (data not shown). Core and coat were clearly distinguished from one 
another, with a small region (10 µm) of intermigration in between.  
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Figure 4. Raman mapping of ASA in co-extrudate F1. A red color corresponds to a high peak 
intensity in the 745-760 cm−1 region, indicating the presence of ASA in the core. A blue color 
corresponds to a very low peak intensity, indicating the absence of ASA in the coat. A very low 
peak intensity was found in the coat at the interface with the core (light blue), indicating very 
little migration of ASA to the coat. 
 
 
Figure 5. Selected region of the Raman spectra of FF, light blue area (Fig. 5), yellow area (Fig. 
5), ASA. 
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The FF release from F1, F2, F3 and F4 was complete in 20, 30, 60 and 60 min, respectively 
(Fig. 6) and was not considered significantly different from the dissolution of the individual coat 
formulations during screening. Furthermore, the Kollidon® VA 64-based coat of F1 and F2 did 
not influence ASA release from the cores. ASA release from the Kollidon® VA 64 core (F4) was 
clearly hindered by the Soluplus® coat. In comparison with the ASA release observed during the 
polymer screening (individual core), the ASA release rate from co-extrudate F4 was significantly 
decreased (complete release after ± 60 min instead of 20 min). It was hypothesized that the 
Soluplus®-based coat partially covered the core surface during dissolution, thereby hindering 
ASA release.  
 
 
Figure 6. Mean FF () and ASA ( ) dissolution profiles (±S.D.) (n = 3) of co-extruded 
formulations (Table 4). 
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After 6 months of storage at ambient conditions (25 °C), all dissolution profiles were 
identical. The DSC thermograms of the coat (FF) remained unchanged, whereas a small ASA 
fraction (±1.5%) had recrystallized in the core of the co-extruded formulations. Furthermore, the 
SA concentration had increased significantly from 1.7 ± 0.12 (F1 and F3) and 2.3 ± 0.29 (F2 and 
F4) immediately after production to 7.4 ± 0.62 (F1), 9.8 ± 0.74 (F2), 9.7 ± 0.58 (F3) and 11.0 ± 
0.98 (F4) after 6 months of storage. These results revealed that, although HME is often proposed 
as formulation technique for overcoming hydrolytic sensitivity, ASA was not stable in any of the 
co-extruded formulations.  
 
4. Conclusions 
This study identified co-extrusion as a promising technique to produce a multilayer FDC 
solid dosage form for oral application characterized by immediate release from both layers. 
Extrusion of ASA was challenging as in some carriers degradation to SA was observed, despite 
of the absence of water during thermal processing. However, core/coat dosage forms were 
successfully developed using four different polymer combinations: Kollidon® PF 12/Kollidon® 
VA 64, Kollidon® PF 12/Soluplus®, Kollidon® VA 64/Kollidon® VA 64 and Kollidon® VA 
64/Soluplus®. All combinations showed good processability via co-extrusion, and the adhesion 
between core and coat was good. The solid state characterization revealed that both ASA and FF 
were molecularly dispersed in the co-extrudates. Raman mapping exposed very little 
intermigration of both drugs at the interface. 6 months of storage at ambient conditions revealed 
that ASA was not stable in any of the co-extruded formulations.   
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1. Introduction 
Hot-melt extrusion (HME) and co-extrusion are valuable and versatile processing 
techniques for drug delivery systems with an exciting future within the pharmaceutical 
industry because they can be operated as continuous processes. In previous chapters (2 and 3) 
it was demonstrated that co-extrusion offers the extra opportunity (over HME) to combine 
different polymers in a co-extruded dosage form, through which drugs can be released with 
different release rates.  
 In chapter 4 it was shown that co-extrusion is also a suitable method for the 
production of fixed-dose combinations with both layers providing immediate release. Yet it 
can be questioned if in that case it is required to formulate the drugs in different layers. After 
all, in comparison to conventional HME, co-extrusion involves additional technical 
considerations (similar extrusion temperatures of the melts, melt viscosity matching and 
adhesion between the layers). The aim of the present study was to examine if co-extrusion 
offered an added value over conventional HME. Therefore, in this study the components of 
co-extruded formulations (developed in chapter 4) were blended and extruded. The 
processability, drug release, SA content and solid state characteristics of the blends were 
compared to those of the corresponding co-extrudates. 
  
2. Materials and methods 
2.1. Materials 
The following polymers were used: Soluplus®, Kollidon® VA 64 and PF 12 (BASF, 
Ludwigshafen, Germany). Fenofibrate (FF, Roig-Farma, Barcelona, Spain) and acetylsalicylic 
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acid (ASA, Utag, Amsterdam, The Netherlands) were incorporated as hydrophobic and 
hydrophilic model drug, respectively. All other chemicals were of analytical grade. 
 
2.2. Production of co-extrudates 
Polymer and drug were premixed in a tumbling mixer (Turbula® T2A, W.A. 
Bachofen, Basel, Switzerland) for 20 min. Co-extrusion was performed using two co-rotating, 
fully intermeshing twin screw extruders (Prism Eurolab 16, ThermoFisher Scientific, 
Germany). The multimanifold co-extrusion die (Guill, West Warwick, USA) was connected 
to both extruders. Both melts were combined in the die to form two concentric layers, a core 
and a coat. Table 1 shows the composition of the co-extruded formulations as well as the 
extrusion conditions used for each formulation. All five heating segments of both extruders 
were set at the same temperature, except for the first heating zone which was set at 70 °C to 
avoid sticking of the powder in the feed section. The premixes were fed into the 
corresponding extruders using loss-in-weight powder feeders (Brabender Flexwall®, 
Duisburg, Germany). The screw speed was kept constant at 120 rpm (core) and 180 rpm 
(coat). The co-extrusion die was designed with a core diameter of 2 mm and a coat thickness 
of 1 mm, resulting in a total die diameter of 4 mm. After cooling down to room temperature, 
the cylindrical co-extrudates were manually cut into mini-matrices of 2 mm length.  
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Table 1. Composition and extrusion parameters of co-extruded formulations. 
 Carrier Drug concentration (%) Extrusion temperature (°C) Feed rate (g/h) 
 Core Coat Core (ASA) Coat (FF) Core Coat Die Core Coat 
F1 Kollidon® PF 12 Kollidon® VA 64 20 20 120 130 95 300 545 
F2 Kollidon® VA 64 Kollidon® VA 64 20 20 130 130 105 300 545 
F3 Kollidon® PF 12 Soluplus® 20 20 120 100 95 300 545 
F4 Kollidon® VA 64 Soluplus® 20 20 130 105 105 300 545 
 
 
2.3. Production of extrudates 
The components of formulations F1-F4 were blended and extruded. Besides, mixtures 
composed of both drugs and a single carrier were also extruded. The extrudates were 
evaluated for processability, macroscopic properties (visual inspection of surface, die swell 
quantification using marking gauge), salicylic acid content (ASA formulations) and in vitro 
drug release. The mixtures were hot-melt extruded using a co-rotating, fully intermeshing 
twin screw extruder (Prism Eurolab 16, ThermoFisher Scientific, Germany) having a length-
to-diameter ratio of 25/1. The co-rotating screws consisted of three mixing sections and a 
densification zone. A strand die with a diameter of 4 mm was mounted at the end of the 
extruder. The extrusion temperature varied according to the formulation, but all five heating 
segments of the extruder were set at the same temperature, except for the first heating zone 
which was set at 70 °C to avoid sticking of the powder in the feed section. The premixes were 
fed into the extruder using a loss-in-weight powder feeder (Brabender flexwall®, Duisburg, 
Germany). The feed rate and screw speed were kept constant at 600 g/h and 180 rpm, 
respectively. After cooling down to room temperature, the cylindrical extrudates were 
manually cut into mini-matrices of 2 mm length. The dimensions of the resulting extrudates 
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were 4 x 2 mm. The composition and extrusion temperature of the hot-melt extruded 
formulations are shown in Table 2. 
 
Table 2. Composition and extrusion temperature of hot-melt extruded formulations. 
 Composition (%) Extrusion temperature (°C) 
 ASA FF Kollidon® PF 12 Kollidon® VA 64 Soluplus® Barrel                  Die 
F1’ 7.1 12.9 28.4 51.6 - 130 95 
F2’ 7.1 12.9 - 80 - 130 105 
F3’ 7.1 12.9 28.4 - 51.6 120 95 
F4’ 7.1 12.9 - 28.4 51.6 130 105 
F5 7.1 12.9 80 - - 120 95 
F6 7.1 12.9 - - 80 105 105 
 
 
2.4. Determination of free salicylic acid 
The salicylic acid (SA) content in the extrudates was assessed according to the USP 32 
monograph for Aspirin tablets.  
 
2.5. In vitro drug release 
Dissolution studies were performed using USP apparatus 1 (baskets). The equipment 
consisted of a VK 7010 dissolution system combined with a VK 8000 automatic sampling 
station (VanKel Industries, NJ, USA). Acetate buffer pH 4.5 containing 0.05 M sodium lauryl 
sulfate was used as dissolution medium. Sink conditions were maintained during the 
experiments. The temperature of the dissolution medium (900 ml) was kept constant at 37 ± 
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0.5 °C. The rotational speed of the baskets was set to 100 rpm. Samples (5 ml) were 
withdrawn at 5, 10, 15, 20, 30, 45, 60 (and 90) min.  
ASA and FF concentration were determined using a validated HPLC method. The 
HPLC equipment (Merck-Hitachi, Darmstadt, Germany) consisted of a gradient solvent pump 
set at a constant flow rate of 1 ml/min, an autosampler, a reversed-phase C-18 column 
(LiChrospher® 100 RP-18 (5 μm)) (250 x 4 mm) and guard column (4 x 4 mm) and a UV 
detector set at 285 nm. The injection volume was 20 µl. An automatic integration system 
(software D-7000 Multi-Manager) was used for peak integration. The mobile phase consisted 
of mixtures of buffer solution pH 2.9 (prepared by dissolving 136 mg of monobasic potassium 
phosphate in 1000 mL of distilled water and adjusting the pH with dilute phosphoric acid to 
2.9 ± 0.05 [1] and methanol: initially using a 57:43-ratio (to elute ASA and SA, while FF was 
retained on the column), after 14.5 min the ratio of the mobile phase was rapidly changed to 
10:90 90% methanol (to elute the hydrophobic FF from the column), after 22.0 min the ratio 
between the aqueous and organic phase was again set at 57:43 and the column was 
equilibrated until 31.0 min prior to the following analysis.  
 
2.6. Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was used to study the solid state properties of 
the extrudates. The thermal behavior of the individual components, physical mixtures and 
extrudates was evaluated using a Q2000 DSC (TA Instruments, Leatherhead, UK). The 
system was equipped with a refrigerated cooling system. Samples (5-10 mg) were accurately 
weighed and hermetically sealed in aluminum pans (TA Instruments, Leatherhead, UK).They 
were cooled to -70 °C, followed by heating to 170 °C at a linear heating rate of 10 °C/min. 
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3. Results and discussion 
In order to examine if co-extrusion offered an added value over HME the 
processability, drug release, SA content and solid state characteristics of the blends were 
compared to those of the corresponding co-extrudates. Extrudates composed of both drugs 
and a single carrier were also characterized. All mixtures were processable via hot-melt 
extrusion at the specified temperatures (Table 2). The resulting extrudates were rigid and 
exhibited a smooth surface. One formulation (F4’) showed significant die swell (6 mm). Fig. 1 
shows the FF release from the extruded blends in comparison with the corresponding co-
extrudates. In general, the FF release rate from the blend extrudates was lower compared to 
the co-extruded formulations (similarity factor <50). Full FF release was observed within 20, 
30, 60 and 60 min for F1, F2, F3, F4 and after 30, 45, >60 and >60 min for F1’, F2’, F3’, F4’, 
respectively. The difference in FF release was most pronounced for formulations F3’ and F4’, 
which both contained Soluplus®. Apparently, the use of a combination of Soluplus® and a 
Kollidon® polymer hindered the matrix disintegration, whereby the FF release was delayed 
(which was in agreement with the visual observation). The difference between F2 and F2’ 
could be explained by the difference in diffusion depth. For formulations F1 and F1’, the 
difference in FF release was small.  
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Figure 1: Comparison of FF release from () coat of co-extrudates and () blend extrudates: 
F1 and F1’, F2 and F2’, F3 and F3’, F4 and F4’. 
 
The ASA release from the extruded blends in comparison to the corresponding co-
extrudates is represented in Fig. 2. Whereas there was a small difference in release between 
F1’ and F1 (similarity factor <50), the release of F2’ equaled that of F2 (similarity factor >50). 
The remarkably lower ASA release rate from F3’ and F4’ in comparison to their corresponding 
co-extrudates could again be explained by the presence of Soluplus®. A supplementary 
dissolution test of a formulation composed of 20% ASA (molecularly dispersed) in Soluplus® 
demonstrated that Soluplus® improved the ASA release rate (100% release after 60 min) to a 
lower extent than the Kollidon® polymers (100% release after 10-20 min). Furthermore, as 
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also described for the FF release, the combination of Soluplus® and a Kollidon® polymer 
resulted in a slower matrix disintegration, whereby the ASA release rate was lowered in 
comparison with matrices composed of one of the polymers. 
 
 
Figure 2: Comparison of ASA release from () core of co-extrudates and () blend 
extrudates: F1 and F1’, F2 and F2’, F3 and F3’, F4 and F4’. 
 
The dissolution profiles of formulations F5 and F6 are shown in Fig. 3. The ASA and 
FF release from Kollidon® PF 12 (F5) was already complete in 15 min. The release rate 
exceeded those of all co-extruded formulations (F1-F4). ASA and FF release from Soluplus® 
(F6) was incomplete after 1 h. During previous studies it was already demonstrated that 
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despite its micellar character, Soluplus® does not always enhance drug release. Whereas 
diclofenac sodium release from Soluplus® matrices was complete in 30 min (chapter 3), 
hydrochlorothiazide release was incomplete after 1 h (chapter 2) and FF release rate (chapter 
4) was lower than expected. A recent study revealed that Soluplus® can be used to delay the 
release of water soluble drugs as well as being used as solubilizer in case of poorly water 
soluble drugs [2]. 
 
 
Figure 3: Mean FF () and ASA ( ) dissolution profiles (±S.D.) (n = 3) of blend extrudates 
F5 and F6. 
 
The SA content of the blend extrudates were respectively 1.03 (± 0.13), 0.72 (± 0.08), 
1.08 (± 0.11) and 1.81 (± 0.15)% for F1’, F2’, F3’ and F4’, while in the core of the respective 
co-extrudates 1.7 (± 0.12) (F1 and F3) and 2.3 (± 0.29) (F2 and F4) % SA was found. 
Comparison of the SA content in blend versus co-extruded formulations pointed out that the 
conventional hot-melt extrusion process was slightly favorable in terms of ASA stability. This 
could be explained by the higher shear forces (higher torque, higher die pressure, smaller die) 
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to which ASA was exposed during co-extrusion in comparison to HME (Table 3). The SA 
concentration of F5 and F6 was 1.34 (± 0.21) and 0.77 (± 0.10), respectively.  
 
Table 3. Comparison of the extruder torque and die pressure between core of co-extruded 
formulation and blend formulation. 
 Torque (% motor load) Die pressure (bar) 
F1 80 25 
F1’ 65 1 
F2 80 40 
F2’ 70 1 
F3 80 25 
F3’ 40 1 
F4 80 40 
F4’ 55 1 
 
 
The solid state of the blend extrudates (F1’-F4’) and F5 and F6 was characterized using 
DSC. As described in chapter 4 no drug crystals were detected in any co-extruded 
formulation. DSC exposed a crystalline ASA fraction of 22.1, 37.9, 42.1 and 16.9% in F1’, F2’, 
F4’ and F5. As an example, the solid state comparison between co-extruded formulation F2 and 
blend formulation F2’ is shown in Fig. 4. These intermediate forms containing both crystalline 
and amorphous drug are undesirable from a stability point of view as there is a higher risk for 
the amorphous fraction to recrystallize.  
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Figure 4: Solid state comparison between co-extruded formulation F2 and blend formulation 
F2’. From top to bottom: ASA, FF, Kollidon® VA 64, physical mixture of F2’, core of co-
extruded formulation F2, coat of co-extruded formulation F2, extrudate F2’. 
 
4. Conclusions 
This study showed that fixed-dose combinations with immediate drug release can be 
produced via HME and that it will not always be mandatory to proceed to co-extrusion. Using 
Kollidon® PF 12 as a carrier, a hot-melt extruded formulation was developed providing 
immediate release of both drugs (within 15 min). The conventional hot-melt extrusion process 
was slightly favorable in terms of ASA stability (lower SA content).  
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The overall aim of this project was to evaluate the potential of hot-melt co-extrusion 
for the production of multilayer oral dosage forms.  
Hot-melt co-extrusion seemed a promising technique to produce in a single step fixed-
dose combination (FDC) mini-matrices. A core/coat dosage form was developed, wherein the 
core and coat exhibited sustained and immediate release properties, using a combination of 
polycaprolactone (core) and PEO/PEG (coat). There was good adhesion between the two 
layers. The in vivo performance of the test formulation was not significantly different from 
that of a reference formulation. 
Co-extrusion also proved to be a promising technique to produce multilayer mini-
matrices with dual drug release. Core/coat dosage forms were developed using two different 
polymer combinations (ethylcellulose/Soluplus® and polycaprolactone/PEO). Co-extruded 
formulations composed of polycaprolactone (core) and PEO/PEG (coat) were preferable 
because they allowed extrusion at a lower temperature and they provided better mechanical 
properties. Furthermore, the adhesion force between the two layers depended on extrusion 
temperature and drug load. By varying the DS ratio in coat and core, the in vitro and in vivo 
drug release could be controlled, demonstrating the flexibility of the dosage form. 
Furthermore, a multilayer FDC solid dosage form characterized by immediate release 
from both layers was developed via co-extrusion. Extrusion of ASA was challenging as in 
some carriers degradation to SA was observed, despite of the absence of water during thermal 
processing. However, core/coat dosage forms were successfully developed using four 
different polymer combinations: Kollidon® PF 12/Kollidon® VA 64, Kollidon® PF 
12/Soluplus®, Kollidon® VA 64/Kollidon® VA 64 and Kollidon® VA 64/Soluplus®. All 
combinations showed good processability via co-extrusion, and the adhesion between core 
and coat was good. Very little intermigration of both drugs was exposed at the interface.  
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The final part of this study showed that fixed-dose combinations with immediate drug 
release can be produced via HME and that it will not always be mandatory to proceed to co-
extrusion. Using Kollidon® PF 12 as a carrier, a hot-melt extruded formulation was developed 
providing immediate release of both drugs (within 15 min). The conventional hot-melt 
extrusion process was slightly favorable in terms of ASA stability (lower SA content).  
Overall, this research project has shown that hot-melt co-extrusion is a promising and 
versatile technique to produce in a single step multilayer oral solid dosage forms. 
Nevertheless, an extension of this project is essential to fully investigate the potential of co-
extrusion applications for oral drug delivery, such as the combination of two sustained release 
layers in a co-extruded dosage form. Other aspects that are worthwhile exploring are: (1) 
combining more than two different layers with different drugs; (2) producing different shapes 
of co-extruded formulations, e.g. multilayer sheets instead of concentric core/coat systems; 
(3) formulating non-compatible drugs into different layers and investigating the 
(in)compatibility at the interface; (4) exploring the use of enteric coating polymers and their 
compatibility with immediate/sustained release polymers; (5) synthetizing “tailor made” 
polymers for co-extrusion that exhibit the desired properties in terms of processability, drug 
release profile, adhesion, etc. 
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Despite more than half a century of experience in the plastics and food industry, hot-
melt co-extrusion is a relatively new technology in the pharmaceutical industry. Recently, it 
has been promoted as an innovative continuous technology providing great potential for the 
production of drug delivery systems. Except from an implant (Implanon®) and a vaginal ring 
(Nuvaring®), there are no co-extruded dosage forms on the market so far. Therefore, the aim 
of this work was to evaluate the potential of co-extrusion for the production of oral solid 
dosage forms. Polymers were characterized and on the basis thereof combined into multilayer 
dosage forms offering immediate release, controlled release or a combination hereof. Using 
different model drugs parameters such as processability, in vitro drug release and solid state 
characteristics were evaluated. Additionally, a stability and in vivo study were performed for 
some selected formulations. 
Chapter 1 described the polymer characteristics relevant for hot-melt co-extrusion. 
Several polymers were screened on the basis of their thermal behavior (glass transition 
(Tg)/melting temperature (Tm), thermal stability), melt flow index and processability via hot-
melt extrusion. Taking into account the Tg/Tm, the minimum extrusion temperature, the 
degradation temperature and the melt viscosity CAPA® 6506, Polyox® WSR N10 and 
Eudragit® E PO demonstrated good suitability for pharmaceutical hot-melt extrusion. Pure 
Soluplus® and Kollidon® SR also showed good extrudability, but within a narrow temperature 
range. Extrusion of Eudragit® RS PO without any plasticizer was not possible because the 
required temperature approached the degradation temperature of the polymer. Ethocel® std 10 
and Kollidon® 30 will require a plasticizer because of their high Tg, melt viscosity and a too 
small difference between Tg and degradation temperature in case of Kollidon® 30. 
Chapter 2 evaluated hot-melt co-extrusion as manufacturing technique for multilayer 
(core/coat) dosage forms, the core providing sustained drug release and the coat immediate 
drug release. In this study polymers were selected which can be combined in a co-extruded 
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dosage form. Several thermoplastic polymers were hot-melt extruded and evaluated for 
processability and macroscopic properties (surface smoothness, die swell). Metoprolol tartrate 
(MPT) and hydrochlorothiazide (HCT) were incorporated as sustained and immediate release 
model drugs, respectively. Based on the polymer screening experiments a combination of 
polycaprolactone (core) and polyethylene oxide (coat) was selected for co-extrusion trials, 
taking into account their drug release profiles and extrusion temperature (70 °C). This 
combination (containing 10% HCT in the coat and 45% MPT in the core) was successfully 
co-extruded (diameter core: 3 mm/thickness coat: 0.5 mm). Adhesion between the two 
polymer layers was good. HCT release from the coat was complete within 30 min, while MPT 
release was sustained over 24 h (55%, 70%, 85% and 100% after 4, 8, 12 and 24 h, 
respectively). DSC, XRD and Raman spectroscopy revealed that MPT remained crystalline 
during extrusion, whereas HCT was dissolved in the polyethylene oxide matrix. The in vivo 
study revealed no significant differences between the experimental formulation and the 
reference formulation (Zok-Zid® tablet). Fixed-dose combination mini-matrices with good in 
vitro and in vivo performance were successfully developed by means of co-extrusion, using a 
combination of polycaprolactone and polyethylene oxide. 
Chapter 3 assessed hot-melt co-extrusion for the development of a multilayered 
dosage form characterized by a dual release profile of the same drug. Co-extrudates consisted 
of two concentric polymer matrices: a core having a lipophilic character and a coat with a 
hydrophilic character. Diclofenac sodium (DS) was incorporated as model drug in both layers. 
Several polymers were screened on the basis of their processability via hot-melt extrusion 
(HME) and in vitro drug release. Polymer combinations with suitable properties (i.e., similar 
extrusion temperature, appropriate drug release profile) were processed via co-extrusion. (Co-
) extruded samples were characterized in terms of solid state (XRD, SEM), in vitro drug 
release, core/coat adhesion, and bioavailability. Based on the polymer screening, two polymer 
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combinations were selected for co-extrusion: ethylcellulose (core) combined with Soluplus® 
(coat) and polycaprolactone (core) with PEO (coat). These combinations were successfully 
co-extruded. XRD revealed that DS remained crystalline during extrusion in ethylcellulose, 
Soluplus®, polycaprolactone, and PEO. The polycaprolactone/PEO combination could be 
processed at a lower temperature (70 °C), vs. 140 °C for ethylcellulose/Soluplus®. The 
maximum drug load in core and coat depended on the extrusion temperature and the die 
dimensions, while adhesion between core and coat was mainly determined by the drug load 
and by the extrusion temperature. In vitro drug release from the co-extruded formulations was 
reflected in the in vivo behavior: formulations with a higher DS content in the coat (i.e., faster 
drug release) resulted in higher Cmax and higher AUC values. Multilayer dosage form with 
dual drug release were successfully developed by means of co-extrusion. 
Chapter 4 evaluated the use of hot-melt co-extrusion for the production of a 
multilayer fixed-dose combination solid dosage form for oral application characterized by 
immediate release for both layers, the layers containing different drugs with different water-
solubility. In this study polymers were selected which can be combined in a co-extruded 
dosage form. Several polymers were screened on the basis of their processability via hot-melt 
extrusion, macroscopic properties, ASA decomposition and in vitro drug release. 
Acetylsalicylic acid (ASA) and fenofibrate (FF) were incorporated as hydrophilic and 
hydrophobic model drugs, respectively. Based on the polymer screening experiments 
Kollidon® PF 12 and Kollidon® VA 64 were identified as useful ASA carriers (core), while 
Soluplus®, Kollidon® VA 64 and Kollidon® 30 were applicable as FF carriers (coat). The 
combination of Kollidon® 30 (coat) with Kollidon® PF 12 or Kollidon® VA 64 (core) failed in 
terms of processability via co-extrusion. All other combinations (containing 20% ASA in the 
core and 20% FF in the coat) were successfully co-extruded (diameter core: 2 mm / thickness 
coat: 1 mm). All formulations showed good adhesion between core and coat. ASA release 
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from the core was complete within 15-30 min (Kollidon® PF 12) or 30-60 min (Kollidon® VA 
64), while FF release was complete within 20-30 min (Kollidon® VA 64) or 60 min 
(Soluplus®). DSC and XRD revealed that both drugs were molecularly dispersed in the 
carriers. Raman mapping exposed very little intermigration of both drugs at the interface. 
Fixed-dose combinations with good in vitro performance were successfully developed by 
means of co-extrusion, both layers providing immediate release. 
 Chapter 5 investigated if co-extrusion offered an added value over hot-melt 
extrusion. Components of co-extruded formulations were blended (in the same ratio as in the 
co-extruded formulations) and extruded. The processability, drug release and solid state 
characteristics of the blends were compared to those of the corresponding co-extrudates. 
Extrudates composed of both drugs and a single carrier were also characterized. Using 
Kollidon® PF 12 as a carrier, a hot-melt extruded formulation was developed providing 
immediate release of both drugs (within 15 min). The conventional hot-melt extrusion process 
was slightly favorable in terms of ASA stability (lower SA content). This study showed that 
fixed-dose combinations with immediate drug release can be produced via HME and that it 
will not always be mandatory to proceed to co-extrusion. 
It can be concluded that hot-melt co-extrusion is a promising and versatile technique 
to produce – in a single step – multilayer oral solid dosage forms.  
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Ondanks meer dan een halve eeuw ervaring in de plastic- en voedingsindustrie, is ‘hot-
melt’ co-extrusie een relatief nieuwe technologie in de farmaceutische industrie. Co-extrusie 
werd recentelijk naar voren gebracht als een innovatieve techniek met veel potentieel voor de 
productie van geneesmiddeltoedieningssystemen. Met uitzondering van een implantaat 
(Implanon®) en een vaginale ring (Nuvaring®), zijn er tot op heden geen geco-extrudeerde 
doseringsvormen op de markt. Bijgevolg was het doel van dit werk om het potentieel van co-
extrusie voor de productie van orale vaste doseringsvormen te evalueren. Polymeren werden 
gekarakteriseerd en op basis daarvan gecombineerd in meerlagige doseringsvormen met 
onmiddellijke of vertraagde vrijstelling of een combinatie van beide. Gebruik makend van 
verschillende modelgeneesmiddelen werden parameters zoals verwerkbaarheid, in vitro 
geneesmiddelvrijstelling en vaste toestand karakteristieken geëvalueerd. Bovendien werd een 
stabiliteits- en een in vivo studie uitgevoerd voor enkele geselecteerde formulaties. 
Hoofdstuk 1 beschreef de polymeerkarakteristieken, die relevant zijn voor ‘hot-melt’ 
co-extrusie. Verschillende polymeren werden gescreend op basis van hun thermische 
eigenschappen (glastransitietemperatuur (Tg)/smeltpunt (Tm), thermische stabiliteit), ‘melt 
flow’ index en verwerkbaarheid via ‘hot-melt’ extrusie (HME). Gezien hun Tg/Tm, minimale 
extrusietemperatuur, degradatietemperatuur en smeltviscositeit bleken CAPA® 6506, Polyox® 
WSR N10 en Eudragit® E PO geschikte polymeren voor farmaceutische HME. Zuiver 
Soluplus® en Kollidon® SR waren ook vlot extrudeerbaar, echter binnen een nauw 
temperatuurgebied. Puur Eudragit® RS PO (zonder weekmaker) was niet extrudeerbaar 
aangezien de temperatuur die hiervoor vereist was de degradatietemperatuur van het polymeer 
benaderde. Ethocel® std 10 en Kollidon® 30 zullen een weekmaker vereisen omwille van hun 
hoge Tg, smeltviscosititeit en door een te klein verschil tussen Tg en degradatietemperatuur in 
het geval van Kollidon® 30. 
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Hoofdstuk 2 evalueerde ‘hot-melt’ co-extrusie als productietechniek voor meerlagige 
(kern/omhulsel) doseringsvormen, waarin de kern zorgde voor een vertraagde en het omhulsel 
voor een onmiddellijke geneesmiddelvrijstelling. In deze studie werden polymeren 
geselecteerd die gecombineerd kunnen worden in een geco-extrudeerde doseringsvorm. 
Verschillende thermoplastische polymeren werden ‘hot-melt’ geëxtrudeerd en geëvalueerd op 
verwerkbaarheid en macroscopische eigenschappen (gladheid van het oppervlak, zwelling van 
het extrudaat). Metoprolol tartraat (MPT) en hydrochloorthiazide (HCT) werden 
geïncorporeerd als modelgeneesmiddelen voor respectievelijk vertraagde en onmiddellijke 
vrijstelling. Op basis van de resultaten van de polymeerscreening werd een combinatie van 
polycaprolacton (kern) en polyethyleenoxide (omhulsel) weerhouden voor co-extrusie 
experimenten, rekening houdende met hun geneesmiddelvrijstellingsprofiel en 
extrusietemperatuur (70 °C). Deze combinatie (bevattende 10% HCT in het omhulsel en 45% 
MPT in de kern) werd met succes geco-extrudeerd (diameter kern: 3 mm/dikte omhulsel: 0,5 
mm). De adhesie tussen de twee polymeerlagen was goed. HCT was binnen 30 min volledig 
vanuit het omhulsel vrijgesteld, terwijl MPT over een periode van 24 uur werd vrijgesteld 
(55%, 70%, 85% en 100% na respectievelijk 4, 8, 12 en 24 u). Dynamische 
differentiecalorimetrie (DSC), X-straal diffractie (XRD) en Raman spectroscopie onthulden 
dat MPT kristallijn bleef gedurende extrusie, terwijl HCT opgelost was in de 
polyethyleenoxide matrix. De in vivo studie kon geen significante verschillen aan het licht 
brengen tussen de experimentele formulatie en de referentieformulatie (Zok-Zid® tablet). 
‘Fixed-dose combination’ (FDC) mini-matrices met goede in vitro en in vivo eigenschappen 
werden met succes ontwikkeld door middel van co-extrusie, gebruik makend van een 
combinatie van polycaprolacton en polyethyleenoxide. 
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Hoofdstuk 3 ging na of ‘hot-melt’ co-extrusie toeliet meerlagige doseringsvormen 
gekarakteriseerd door een tweeledige vrijstelling van eenzelfde geneesmiddel, te ontwikkelen. 
De co-extrudaten bestonden uit twee concentrische polymeermatrices: een kern met een 
lipofiel en een omhulsel met een hydrofiel karakter. Natrium diclofenac (DS) werd 
geïncorporeerd als modelgeneesmiddel in beide lagen. Verschillende polymeren werden 
gescreend op basis van hun verwerkbaarheid via HME en in vitro geneesmiddelvrijstelling. 
Polymeercombinaties met geschikte eigenschappen (d.i. gelijkaardige extrusietemperatuur, 
geschikt geneesmiddelvrijstellingsprofiel) werden geco-extrudeerd. Ge(co-)extrudeerde stalen 
werden gekarakteriseerd in termen van vaste toestand karakteristieken (XRD, SEM), in vitro 
geneesmiddelvrijstelling, adhesie tussen kern en omhulsel en biologische beschikbaarheid. 
Gebaseerd op de polymeerscreening werden twee polymeercombinaties geselecteerd voor co-
extrusie: ethylcellulose (kern) in combinatie met Soluplus® (omhulsel) en polycaprolacton 
(kern) met polyethyleenoxide (omhulsel). Deze combinaties werden succesvol geco-
extrudeerd. XRD toonde aan dat DS kristallijn bleef gedurende extrusie in ethylcellulose, 
Soluplus®, polycaprolacton en polyethyleenoxide. De polycaprolacton/polyethyleenoxide 
combinatie kon verwerkt worden bij een lagere temperatuur (70 °C), t.o.v. 140 °C voor 
ethylcellulose/Soluplus®. De maximaal mogelijke geneesmiddelbelading in kern en omhulsel 
hing af van de extrusietemperatuur en matrijsafmetingen, terwijl de adhesie tussen kern en 
omhulsel voornamelijk bepaald werd door geneesmiddelbelading en extrusietemperatuur. De 
in vitro geneesmiddelvrijstelling vanuit de geco-extrudeerde formulaties werd weerspiegeld in 
hun in vivo gedrag: formulaties met een hoger DS gehalte in het omhulsel (d.i. snellere 
vrijstelling) resulteerden in een hogere Cmax en hogere AUC waarden. Meerlagige 
doseringsvormen met tweeledige geneesmiddelvrijstelling werden met succes ontwikkeld 
m.b.v. co-extrusie. 
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Hoofdstuk 4 evalueerde het gebruik van ‘hot-melt’ co-extrusie voor de productie van 
een meerlagige FDC doseringsvorm, gekarakteriseerd door een onmiddellijke vrijstelling 
vanuit beide lagen en waarin de lagen geneesmiddelen met verschillende oplosbaarheden 
bevatten. In deze studie werden polymeren geselecteerd die gecombineerd kunnen worden in 
een geco-extrudeerde doseringsvorm. Verschillende polymeren werden gescreend op basis 
van hun verwerkbaarheid via HME, macroscopische eigenschappen, acetylsalicylzuur (ASA) 
afbraak en in vitro geneesmiddelvrijstelling. ASA en fenofibraat (FF) werden geïncorporeerd 
als respectievelijk hydrofiel en hydrofoob modelgeneesmiddel. Op basis van de 
polymeerscreening werden Kollidon® PF 12 en Kollidon® VA 64 geïdentificeerd als 
bruikbare ASA dragers (kern), terwijl Soluplus®, Kollidon® VA 64 en Kollidon® 30 geschikt 
waren als FF dragers (omhulsel). Kollidon® 30 (omhulsel) kon niet met Kollidon® PF 12 of 
Kollidon® VA 64 (kern) gecombineerd worden via co-extrusie. Alle andere combinaties 
(bevattende 20% ASA in de kern en 20% FF in het omhulsel) werden succesvol geco-
extrudeerd (diameter kern: 2 mm/dikte omhulsel: 1 mm). Alle formulaties vertoonden goede 
adhesie tussen kern en omhulsel. De ASA vrijstelling vanuit de kern was compleet binnen 15-
30 min (Kollidon® PF 12) of 30-60 min (Kollidon® VA 64), terwijl dat voor FF na 20-30 min 
(Kollidon® VA 64) of 60 min (Soluplus®) was. DSC en XRD onthulden dat beide 
geneesmiddelen moleculair gedispergeerd waren in de dragers. Raman mapping toonde zeer 
weinig intermigratie van beide geneesmiddelen ter hoogte van het grensvlak aan. FDC’s met 
goede in vitro vrijstelling werden ontwikkeld d.m.v. co-extrusie, waarin beide lagen een 
onmiddellijke vrijstelling garandeerden. 
  Hoofdstuk 5 onderzocht of co-extrusie een meerwaarde bood t.o.v. HME. De 
componenten van geco-extrudeerde formulaties werden gemengd (in dezelfde verhouding als 
in de co-extrudaten) en geëxtrudeerd. De verwerkbaarheid, geneesmiddelvrijstelling en vaste 
toestand karakteristieken van de mengextrudaten werden vergeleken met deze van de 
 SAMENVATTING 
 
165 
 
overeenkomstige co-extrudaten. Extrudaten waarbij beide geneesmiddelen in één enkele 
drager waren ingebed, werden ook gekarakteriseerd. Gebruik makend van Kollidon® PF 12 
als drager werd een formulatie ontwikkeld via ‘hot-melt’ extrusie waaruit beide 
geneesmiddelen onmiddellijk (binnen 15 min) werden vrijgesteld. Het conventionele HME 
proces genoot een lichte voorkeur in termen van ASA stabiliteit. Deze studie toonde aan dat 
FDC’s met onmiddellijke geneesmiddelvrijstelling aangemaakt kunnen worden via HME en 
dat het niet steeds nodig zal zijn om, voor deze toepassing, over te gaan tot co-extrusie.  
Er kan besloten worden dat ‘hot-melt’ co-extrusie een veelbelovende en veelzijdige 
techniek is om – in één enkele stap – meerlagige orale vaste doseervormen te produceren. 
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